




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, C07K 14/47, A61K 38/17, 39/395, G01N 33/53, C12Q 1/68, C12N 15/62, 15/11, C07K 16/18, A01K 67/027, A61K 48/00		A2	(11) International Publication Number: WO 99/24571
(21) International Application Number: PCT/US98/23953		(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P. C., One Financial Center, Boston, MA 02111 (US).	
(22) International Filing Date: 10 November 1998 (10.11.98)		(43) International Publication Date: 20 May 1999 (20.05.99)	
(30) Priority Data: 60/065,048 10 November 1997 (10.11.97) US 09/189,618 9 November 1998 (09.11.98) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/065,048 (CIP) Filed on 10 November 1997 (10.11.97)		Published Without international search report and to be republished upon receipt of that report.	
(71) Applicant (for all designated States except US): CURAGEN CORPORATION [US/US]; 11th floor, 555 Long Wharf Drive, New Haven, CT 06511 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US). LOWE, David, G. [US/US]; 35 Via Delizia, Hillsborough, CA 94010 (US).			

(54) Title: **DIFFERENTIALLY EXPRESSED GENES IN CARDIAC HYPERTROPHY AND THEIR USES IN TREATMENT AND DIAGNOSIS**

(57) Abstract

The present invention is based upon the identification of genes which are differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissue. Accordingly, the present invention provides nucleotide sequences of genes selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. The invention also provides therapeutic methods and pharmaceutical compositions, which are based on the promotion or inhibition of the function of the differentially expressed genes. The invention further provides methods of diagnosis, prognosis and screening for a disposition for diseases or disorders associated with cardiac hypertrophy. Methods for screening for modulators of the protein products of the differentially expressed genes in cardiac hypertrophy tissue are additionally provided.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DIFFERENTIALLY EXPRESSED GENES IN CARDIAC HYPERTROPHY AND THEIR USES IN TREATMENT AND DIAGNOSIS**FIELD OF THE INVENTION**

5 The present invention relates to genes which are differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissues. The present invention further relates to the *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8* and *CH-9* genes, which genes have nucleotide homology to, but are not identical to human short-chain alcohol dehydrogenase, mouse amyloid β -peptide binding protein, mouse α -1 Collagen Type III, mouse α -1 Collagen Type IV, chicken Collagen Type XIV, human 13kD DAP, mouse and human Gelsolin, mouse Osteonectin, mouse Transglutaminase, and mouse and human Zyxin, the proteins encoded by these genes, and derivatives and analogs thereof. This invention further provides methods of treating or preventing cardiac hypertrophy based on use of genes and the products of genes

10 differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissue. Additionally, the invention relates to methods of diagnosis, prognosis as well as methods of screening for modulators of the above listed proteins that are protective for cardiac hypertrophy.

15

BACKGROUND OF THE INVENTION

20 Heart failure is often defined as the inability of the heart to deliver a supply of oxygenated blood sufficient to meet the metabolic needs of peripheral tissues, both at rest and during exercise. See generally, Hutter, Jr., "Congestive Heart Failure", in Scientific American: Medicine, Volume 1 (1:II), eds. Dale and Federman (Scientific American, Inc. 1994). Heart failure is a common outcome of hypertension or post-myocardial infarction and is a major contributor to cardiovascular morbidity and mortality. The clinical presentation of heart failure is an energy deprived heart, with altered calcium ion homeostasis, energy metabolism, and decreased contractile reserve (see e.g. Ingwall, *Circulation* 87 (Suppl VII):58-62 (1993)).

25

30 Hypertrophy develops in response to chronic overloading of the heart, such as occurs in systematic hypertension or aortic stenosis. Hypertrophy entails an increase both in size of the individual muscle cells and in the overall muscle mass. While cardiac hypertrophy is thought to be an initial compensatory response to increased hemodynamic load, restoring lost function and

normalizing wall stress, hypertrophy is also an independent risk factor for progression to decompensated heart failure (Kannel, in *Congestive Heart Failure* W. KT, Ed. (WB Saunders Co, 1989) pp. 1-9; A.M. Feldman, *JAMA* 267:1956-61 (1992); Katz, *TCM* 5:37-44 (1995); Konstam, *et al.*, *Circulation* 86:431-438 (1992); Shubeita, *et al.*, *J. Biol. Chem.* 265:2055-20562 (1990)). Clinical trials in heart failure with angiotensin converting enzyme inhibitors suggest
 5 that part of the benefit of these inhibitors derives from attenuation of cardiac hypertrophy, structural remodeling and fibrosis (Chien *et al.*, *FASEB J.* 5:3037-3046 (1991); Boheler *et al.*, *TCM* 2:176-182 (1992)).

Experiments in animal model systems and cell culture have demonstrated that cardiac
 10 hypertrophy is associated with changes in gene expression (Izumo *et al.*, *Proc. Natl. Acad. Sci. USA* 85:339-343 (1988); Calderone *et al.*, *Circulation* 92: 2385-2390 (1995); Boluyt, *et al.*, *Circ. Res.* 75:23-32 (1994); Feldman *et al.*, *Circ. Res.* 73:184-192 (1993); Buttrick *et al.*, *J. Mol. Cell. Cardiol.* 26:61-67 (1994)). The specific pattern of expression differences *in vivo*, referred to as
 15 the molecular phenotype, is dependent on the nature of the hypertrophic stimulus, as well as the stage of compensatory hypertrophy or decompensated failure (Knowlton, *et al.*, *J. Biol. Chem.* 266:7759-7768 (1991); Shubeita, *et al.*, *J. Biol. Chem.* 265:20555-20562 (1990); Pennica, *et al.*, *Proc. Natl. Acad. Sci. USA* 92:1142-1146 (1995); Lai, *et al.*, *Am. J. Physiol.* 271:H2197-H2208 (1996); Eppenberger *et al.*, *TCM* 4:187-193 (1994); Ito *et al.*, *J. Clin. Invest.* 92:398-403 (1993)).
 Studies with cultured cardiomyocytes and non-myocytes have also suggested a role for specific
 20 mediators in the response to increased hemodynamic load including adrenergic stimulation, gp130 signaling, endothelin-1, angiotensin II, and prostaglandin F2 α , each with a distinct expressional and phenotypic response (Anversa *et al.*, *J. Mol. Cell. Cardiol.* 12:781-795 (1980)).

Pressure overload leads to myocardial hypertrophy and the remodeling of muscular and collagenous compartments of the myocardium where the accumulation of fibrillar collagen is
 25 known to impair myocardial stiffness. Pressure overload can be achieved via surgical constriction of the aorta, aortic incompetence and aortocaval fistula (Mercadier *et al.*, *Circ. Res.* 49:525-532 1981)). After abdominal aortic banding, left ventricular weight rises early and reaches a plateau by day 3 (Lindy *et al.*, *Circ. Res.* 20:205-209 (1972); Turto, *Cardiovasc. Res.* 11:358-366 (1977)). Fibroblast proliferation also occurs with pressure overload, starting at day 2
 30 and declining at day 7 after abdominal aortic banding (Morkin *et al.*, *Am. J. Physiol.* 215:1409-1413 (1968)). Pressure overload caused cardiac hypertrophy is also associated with changes in gene expression (Lompre *et al.*, *Int. Cell Rev.* 124:137-186 (1990); Schwartz *et al.*, *Heart Failure* 4:154-163 (1988)). For instance, cardiac hypertrophy secondary to pressure overload is

DIFFERENTIALLY EXPRESSED GENES IN CARDIAC HYPERTROPHY AND THEIR USES IN TREATMENT AND DIAGNOSIS**FIELD OF THE INVENTION**

5 The present invention relates to genes which are differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissues. The present invention further relates to the *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8* and *CH-9* genes, which genes have nucleotide homology to, but are not identical to human short-chain alcohol dehydrogenase, mouse amyloid β -peptide binding protein, mouse α -1 Collagen Type III, mouse α -1 Collagen
10 Type IV, chicken Collagen Type XIV, human 13kD DAP, mouse and human Gelsolin, mouse Osteonectin, mouse Transglutaminase, and mouse and human Zyxin, the proteins encoded by these genes, and derivatives and analogs thereof. This invention further provides methods of treating or preventing cardiac hypertrophy based on use of genes and the products of genes
15 differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissue. Additionally, the invention relates to methods of diagnosis, prognosis as well as methods of screening for modulators of the above listed proteins that are protective for cardiac hypertrophy.

BACKGROUND OF THE INVENTION

20 Heart failure is often defined as the inability of the heart to deliver a supply of oxygenated blood sufficient to meet the metabolic needs of peripheral tissues, both at rest and during exercise. See generally, Hutter, Jr., "Congestive Heart Failure", in Scientific American: Medicine, Volume 1 (1:II), eds. Dale and Federman (Scientific American, Inc. 1994). Heart
25 failure is a common outcome of hypertension or post-myocardial infarction and is a major contributor to cardiovascular morbidity and mortality. The clinical presentation of heart failure is an energy deprived heart, with altered calcium ion homeostasis, energy metabolism, and decreased contractile reserve (see e.g. Ingwall, *Circulation* 87 (Suppl VII):58-62 (1993)).

30 Hypertrophy develops in response to chronic overloading of the heart, such as occurs in systematic hypertension or aortic stenosis. Hypertrophy entails an increase both in size of the individual muscle cells and in the overall muscle mass. While cardiac hypertrophy is thought to be an initial compensatory response to increased hemodynamic load, restoring lost function and

normalizing wall stress, hypertrophy is also an independent risk factor for progression to decompensated heart failure (Kannel, in *Congestive Heart Failure* W. KT, Ed. (WB Saunders Co, 1989) pp. 1-9; A.M. Feldman, *JAMA* 267:1956-61 (1992); Katz, *TCM* 5:37-44 (1995); Konstam, *et al.*, *Circulation* 86:431-438 (1992); Shubeita, *et al.*, *J. Biol. Chem.* 265:2055-20562 (1990)). Clinical trials in heart failure with angiotensin converting enzyme inhibitors suggest
 5 that part of the benefit of these inhibitors derives from attenuation of cardiac hypertrophy, structural remodeling and fibrosis (Chien *et al.*, *FASEB J.* 5:3037-3046 (1991); Boheler *et al.*, *TCM* 2:176-182 (1992)).

Experiments in animal model systems and cell culture have demonstrated that cardiac
 10 hypertrophy is associated with changes in gene expression (Izumo *et al.*, *Proc. Natl. Acad. Sci. USA* 85:339-343 (1988); Calderone *et al.*, *Circulation* 92: 2385-2390 (1995); Boluyt, *et al.*, *Circ. Res.* 75:23-32 (1994); Feldman *et al.*, *Circ. Res.* 73:184-192 (1993); Buttrick *et al.*, *J. Mol. Cell. Cardiol.* 26:61-67 (1994)). The specific pattern of expression differences *in vivo*, referred to as the molecular phenotype, is dependent on the nature of the hypertrophic stimulus, as well as the
 15 stage of compensatory hypertrophy or decompensated failure (Knowlton, *et al.*, *J. Biol. Chem.* 266:7759-7768 (1991); Shubeita, *et al.*, *J. Biol. Chem.* 265:20555-20562 (1990); Pennica, *et al.*, *Proc. Natl. Acad. Sci. USA* 92:1142-1146 (1995); Lai, *et al.*, *Am. J. Physiol.* 271:H2197-H2208 (1996); Eppenberger *et al.*, *TCM* 4:187-193 (1994); Ito *et al.*, *J. Clin. Invest.* 92:398-403 (1993)).
 Studies with cultured cardiomyocytes and non-myocytes have also suggested a role for specific
 20 mediators in the response to increased hemodynamic load including adrenergic stimulation, gp130 signaling, endothelin-1, angiotensin II, and prostaglandin F2 α , each with a distinct expressional and phenotypic response (Anversa *et al.*, *J. Mol. Cell. Cardiol.* 12:781-795 (1980)).

Pressure overload leads to myocardial hypertrophy and the remodeling of muscular and collagenous compartments of the myocardium where the accumulation of fibrillar collagen is
 25 known to impair myocardial stiffness. Pressure overload can be achieved via surgical constriction of the aorta, aortic incompetence and aortocaval fistula (Mercadier *et al.*, *Circ. Res.* 49:525-532 1981)). After abdominal aortic banding, left ventricular weight rises early and reaches a plateau by day 3 (Lindy *et al.*, *Circ. Res.* 20:205-209 (1972); Turto, *Cardiovasc. Res.* 11:358-366 (1977)). Fibroblast proliferation also occurs with pressure overload, starting at day 2
 30 and declining at day 7 after abdominal aortic banding (Morkin *et al.*, *Am. J. Physiol.* 215:1409-1413 (1968)). Pressure overload caused cardiac hypertrophy is also associated with changes in gene expression (Lompre *et al.*, *Int. Cell Rev.* 124:137-186 (1990); Schwartz *et al.*, *Heart Failure* 4:154-163 (1988)). For instance, cardiac hypertrophy secondary to pressure overload is

accompanied by induction of two contractile protein isogenes, β -myosin heavy chain and α -skeletal actin (Swynghedauw, *Physiol. Rev.* 66:710-749 (1986)).

Current clinical and preclinical work suggests that cardiac hypertrophy and heart failure are problems of cardiac growth and morphogenesis. A comprehensive understanding of the molecular phenotype in compensatory and pathological hypertrophy may thus be important to developing novel therapeutic strategies as well as understanding current treatments. However, the technical limitations of the candidate gene paradigm, in which specific genes of interest have been tested one or several at a time for their association with heart disease, mean that relatively little information is available compared to the entire complement of genes expressed in the myocardium.

To obtain a more detailed understanding of the changes in gene expression occurring during pressure overload hypertrophy, the present inventors have used quantitative expression analysis (QEA) to identify expression differences in a rat surgical model of pressure overload (POL) induced cardiac hypertrophy. Abdominal aortic constriction leads to moderate hemodynamic overload (Boheler and Schwartz, *TCM* 2:176-182 (1992); Grossman *et al.*, *J. Clin. Invest.* 56:56-64 (1975)), with the heart responding by concentric hypertrophy of the left ventricle, a process that leads to normalization of systolic wall stress (Morgan and Baker, *Circulation* 83:13-25 (1991)). Although increased load is thought to be the primary stimulus for this response, focal necrosis in the myocardium may also contribute to increased wall stress in this model.

This *in vivo* model is attractive for expression analysis as there are limited changes in tissue cellularity by infiltration of non-resident cells. The tissue reaction to acute POL is primarily due to an intrinsic response of the myocardium including hypertrophy of the cardiomyocytes, in addition to hyperplasia of endothelial, smooth muscle, and mesenchymal cells (Weber and Brilla, *Circulation* 83:1849-1865 (1991); Cooper, IV, *Ann. Rev. Physiol.* 49:501-518 (1987)). While this process is initially adaptive, there is ultimately a deterioration of contractile function accompanied by interstitial and perivascular fibrosis and increased wall stiffness (Kimura *et al.*, *Heart Circ. Physiol.* 25:H1006-H1011 (1989); Batra and Rakusan, *J. Cardiovasc. Pharmacol.* 17 (Suppl 2):S151-S153 (1991)).

30

(1) Proteins Differentially Expressed in Hypertrophic Cardiac Tissue

The present inventors identified the following genes that are differentially expressed in cardiac hypertrophic tissue as compared to normal cardiac tissue: genes similar to the genes

encoding human short-chain alcohol dehydrogenase, mouse amyloid beta-peptide binding protein, mouse α -1 Collagen Type III, mouse α -1 Collagen Type IV, chicken Collagen Type XIV, human 13kD DAP, mouse and human Gelsolin, Osteonectin, mouse Transglutaminase, and mouse and human Zyxin. The present inventors also discovered that the following genes were
5 differentially regulated in the hypertrophic tissue: α -Enolase, Antizyme Inhibitor, Biglycan, Cytochrome Oxidase I, Cytochrome Oxidase II, Cyclin G, D-binding protein, Desmin, Fibrillin, Laminin, Protein kinase C-binding protein α 15, p85, 28S rRNA gene, genes for 5.8S, 18S, and 28S RRNAS, and Preproenkephalin. The present inventors also identified the following genes which previously have been shown to be differentially expressed in hypertrophic cardiac tissue:
10 α -Skeletal Actin, ANF, ANF precursor, Atrial Natriuretic Peptide (ANP), MLC2, α Cardiac MHC, β Cardiac MHC, and Fibronectin.

Antizyme inhibitor is a regulator of antizyme, an enzyme that accelerates the degradation of ornithine decarboxylase (ODC) by the 26 S proteasome. Antizyme inhibitor binds to the antizyme with a higher affinity than does ODC, effecting ODC release from an ODC-antizyme
15 complex. Antizyme inhibitor contains amino acid residues required for formation of active sites of ODC, but it completely lacks ODC activity (Murakami *et al.*, *J. Biol. Chem.* 271(7):3340-3342 (1996)).

Biglycan is a proteoglycan containing one or more glycosaminoglycans moieties (GAG) which are predominantly associated with the extracellular matrix (ECM). In one study, the
20 lowest biglycan mRNA expression in mice was located within the heart, skin and kidney, while the highest was in the lungs, liver and spleen (Wegrowski *et al.*, *Genomic* 30(1):8-17 (1995)). The extracellular matrix proteins collagen, fibronectin, and laminin influence biglycan mRNA expression (Dreher *et al.*, *Eur. J. Cell Biol.* 53(2):296-304 (1990)).

Collagen III is distributed in skin, blood vessels, and internal organs. Chronic
25 hypertension is known to affect collagen levels (Burgess *et al.*, *Am. J. Physiol.* 270(1 Pt 2):H151-159 (1996)). Collagen III is also necessary for Collagen I fibrillogenesis in the cardiovascular region (Lui *et al.*, *Proc. Natl. Acad. Sci. USA* 94(5):1852-1856 (1997)). The ratio between collagen III/I mRNA is a marker for changes in the extracellular matrix associated with hypertrophy (MRNA levels used as indicators).

30 Collagen XIV localizes near the surface of collagen fibrils and may be involved in epithelial-mesenchymal interactions as well as in the modulation of tissue biomechanical properties (Berthod *et al.*, *J. Invest. Dermatol.* 108(5):737-742 (1997)). Collagen XIV is expressed at very few sites in the 6-day-old embryo, but occurs in virtually every collagen I-

containing tissue (skeletal muscle, cardiac muscle, gizzard, tendon, periosteum, nerve) by the end of embryonic development (Walchli *et al.*, *J. Cell Sci.* 107(Pt 2):669-681 (1994)).

Cyclin G contains a typical cyclin box at the N-terminus but no apparent "destruction box" or "PEST" sequence. Interestingly, in its C-terminus region, Cyclin G has a sequence homologous with a tyrosine phosphorylation site of the epidermal growth factor receptor. Although this cyclin is phylogenetically related to HCS26 of *Saccharomyces cerevisiae*, it most resembles Cig1, a B-type cyclin, of *Schizosaccharomyces pombe*, which has been suggested to act at the G1/S phase of the cell cycle. Cyclin G mRNA is induced within 3 hours of growth stimulation and remains elevated with no apparent cell cycle dependency (Tamura *et al.*, *Oncogene*, 8(8):2113-8, (1993)).

Cytochrome C oxidase subunits I and II are two of three mitochondrial DNA encoded subunits of respiratory Complex IV (Kadenbach *et al.*, 1983; Schoffner *et al.*, 1995). Complex IV is located within the mitochondrial inner membrane and is the third and final enzyme of the electron transport chain of mitochondrial oxidative phosphorylation (*Id.*)

Desmin, an intermediate filament protein, is considered a differentiation marker for all muscle types (van Groningen *et al.*, *Biochi. Biophys. Acta* 1217(1):107-109 (1994)). It is distributed throughout the cytoplasm of smooth muscle cells -- linking together adjacent myofibrils in heart and skeletal muscle cells. Because desmin is an intermediate filament, it can withstand larger stretching forces than actin or microtubules -- thereby providing tensile strength and support for the rest of the muscular system. It has been shown that contractile activity and load due to passive stretch increase desmin content in neonatal rat cardiac myocytes through increased desmin gene transcription (Watson *et al.*, *Am. J. Physiol.* 270(4 Pt 1):C1228-1235 ((1996)).

Fibrillin fibers are large glycoproteins that are incorporated in the outer casing of elastic fibers found within most connective tissues. Fibrillin proteins are essential for the integrity of the elastic fibers; and a mutation in the gene results in Marfan's Syndrome (Watkins *et al.*, *Circ. Res.* 60:327-336 (1987); Lockard and Bloom, *J. Mol. Cell Cardiol.* 25:303-309 (1993)).

Gelsolin is a calcium- and phospholipid-dependent modulator of actin. Gelsolin is also considered a marker for oligodendrocytes (Tanaka *et al.*, *Glia* 19(4):286-297 (1997)), and has been shown to be active in adipose tissue (Maeda *et al.*, *Gene* 190(2):227-235 (1997)).

Laminin protein is a part of the extracellular matrix, specifically an integral part of the basal lamina which endothelial cells themselves secrete (Eghbali, *et al.*, *J. Mol. Cell. Cardiol.* 21:103-113 (1989)). Associated with angiogenesis, it is a fibrous protein similar to fibronectin.

Laminin is related to other structural proteins -- collagen III (blood vessel tissue), collagen IV (basal lamina "basement" membrane), and fibronectin (Engelmann *et al.*, *Mol. Cell Biochem.* 163-164:47-56 (1996); Sage, *Nature Med.* 3:144-146 (1997)).

5 Secreted Protein Acidic and Rich in Cysteine (SPARC)/Osteonectin is a Ca^{+2} binding glycoprotein which binds to collagen. When SPARC is added to synovial fibroblasts, 3 metalloproteinase mRNAs, including collagenase, stromelysin, and gelatinase were upregulated, all of which degrade the ECM and basal laminae (Tremble *et al.* *J. Cell Biol.* 121(6):1433-1444 (1993)).

10 The p85/ECM1 sequence has not been reported, but it has been reported to have a structural similarity to serum albumin family proteins and to Endol6 (a calcium-binding protein of sea urchin) particularly because of typical cysteine doublets (Bhalerao *et al.*, *J. Biol. Chem.* 270(27):16385-94, (1995)).

15 Met-enkephalin and leu-enkephalin are pentapeptides which compete for and mimic the effect of opiate drugs (Legon *et al.*, *Nucleic Acids Res.* 10:7905-7918 (1982)). Preproenkephalin mRNA encodes 4 copies of Met-enkephalin, 2 copies of Met-enkephalin extended sequences, and 1 copy of leu-enkephalin (Comb *et al.*, *Nature* 296:663-666 (1982)). Enkephalin-deficient mice were healthy, fertile, and cared for their offsprings but displayed significant behavior abnormalities (Konig *et al.*, *Nature* 383:535-538 (1996)).

20 Transglutaminase (TGase) is a calcium-dependent enzyme which is expressed in a variety of cells and catalyzes the cross-linking of polypeptide chains (glutamine and lysine residues in substrate proteins) -- including ECM related proteins (Johnson *et al.*, *J. Clin. Invest.* 99(12):2950-2960 (1997)). Also, chondrocyte hypertrophy results in an increase in TGase (Nurminskaya & Linsenmayer, *Dev. Dyn.* 206(3):260-271 (1996)). TGase binds and covalently cross-links fibronectin -- and thereby is involved in cellular adhesion, tissue organization, and wound repair
25 (Achyuthan *et al.*, *J. immuno. Methods* 180(1):69-79 (1995)).

A component of adhesion plaques, zyxin (ZN) is involved in the microfilament organization within focal contact sites and is found primarily in cyto-skeleton associated fibroblasts. Reinhard *et al.*, *FEBS Lett.* 399(1-2):103-107 (1996) found that the vasodilator-stimulated phosphoprotein (VASP) acts as a ligand for both profilin and zyxin (both involved in
30 the adherins junctions). Although the putative designation of ZN as an attachment protein to the ECM is substantiated by numerous protein interaction studies, there are two important deviations in the amino acid structure and sequence of ZN compared to other adherin-associated proteins: 1) the amino acid sequence of ZN displays a high degree of similarity with proto-oncogenic

products and transcriptional regulators (Schmeichel & Beckerle, *Mol. Biol. Cell* 8(2):219-230 (1994)). and 2) there are three distinct LIM domains in ZN which are involved in metal binding (Macalma *et al.*, *J. Biol. Chem.* 271(49):31470-31478 (1996)).

It should be noted that citation or discussion of a reference herein shall not be construed
 5 as an admission that such is prior art to the present invention.

SUMMARY OF THE INVENTION

The present inventors have applied quantitative expression analysis to a rat surgical
 10 model of cardiac hypertrophy (RCH) which produces a 60% increase in ventricle mass. The present inventors discovered that, of the 12,000 QEA-generated gene fragments derived from approximately 6,000 genes, 39 fragments (0.3%) were found to be differentially expressed in the hypertrophic hearts relative to controls. The present inventors further discovered that the expression level of a number of genes, not previously associated with cardiac hypertrophy, is
 15 significantly altered in the surgical model of cardiac hypertrophy. Expression of genes with homology to *short-chain alcohol dehydrogenase*, *Desmin*, *Protein Kinase C-Binding Protein β 15* and genes encoding 5.8S, 18S and 28S rRNAs are inhibited, while the expression of genes with homology to mouse *α -1 Collagen Type III*, mouse *α -1 Collagen Type IV*, chicken *Collagen Type XIV*, human *13kD DAP*, mouse and human *Gelsolin*, mouse *Osteonectin*, mouse
 20 *Transglutaminase*, and mouse and human *Zyxin*, as well as the *α -Enolase*, *Antizyme Inhibitor*, *Biglycan*, *Cytochrome Oxidase I*, *Cytochrome Oxidase II*, *Cyclin G*, *Rat D-binding protein*, *Fibrillin*, *Laminin A-1*, *p85* and *Preproenkephalin* genes is induced in the cardiac hypertrophy model. The above-listed genes, both the induced and inhibited genes, are collectively referred to as cardiac hypertrophy associated gene ("CHAG" hereinafter). Accordingly, these identified
 25 CHAG genes, RNA and proteins encoded by CHAG genes are useful in the treatment and prevention of cardiac hypertrophy, and screening for predisposition to or for protection against cardiac hypertrophy.

The present invention further relates to nucleotide sequences of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8* and *CH-9* genes, which have nucleotide sequence homology to
 30 human *short-chain alcohol dehydrogenase* and mouse *amyloid beta-peptide binding protein*, to mouse *α -1 Collagen Type III*, to mouse *α -1 Collagen Type IV*, to chicken *Collagen Type XIV*, to human *13kD DAP*, to mouse and human *Gelsolin*, to mouse *Osteonectin*, to mouse *Transglutaminase*, and mouse and human *Zyxin*, respectively. The present inventors have found

that these genes are differentially expressed in hypertrophic cardiac tissue as compared to normal cardiac tissue. Accordingly, the present invention relates to nucleotide sequences of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8* and *CH-9*, and amino acid sequences of their encoded proteins, as well as derivatives (*e.g.*, fragments) and analogs thereof. Nucleic acids hybridizable,
5 or complementary, or in particular, inversely complementary to the foregoing nucleotide sequences are also provided. In a specific embodiment, the above-listed proteins are human proteins.

The invention also relates to derivatives (including fragments) and analogs of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8* and *CH-9* proteins which are functionally active, *i.e.*,
10 they are capable of displaying one or more known functional activities associated with a full-length (wild-type) protein. Such functional activities include but are not limited to antigenicity [ability to bind (or compete with the above-listed proteins for binding) to an antibody against the above-listed proteins], and immunogenicity (ability to generate antibody which binds to the
15 above-listed proteins).

Antibodies to the above-listed proteins, and derivatives and analogs thereof, are additionally provided.

Methods of production of the proteins encoded by *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8* and *CH-9*, and derivatives and analogs thereof, *e.g.*, by recombinant means, are
20 also provided.

The present invention further relates to therapeutic and diagnostic methods, particularly methods of treating, preventing, diagnosing or screening for cardiac hypertrophy, and compositions based on *CHAG* (*CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, *CH-9*, and α -Enolase, Antizyme Inhibitor, Biglycan, Cytochrome Oxidase I, Cytochrome Oxidase II, Cyclin
25 G, D-binding protein, Desmin, Fibrillin, Laminin A-1, p85, Preproenkephalin, Protein Kinase C-Binding Protein B15, and genes encoding 5.8S, 18S and 28S rRNAs) proteins and nucleic acids. Therapeutic compounds of the invention include but are not limited to *CHAG* proteins and analogs and derivatives (including fragments) thereof; anti-*CHAG* antibodies; nucleic acids encoding the *CHAG* proteins, analogs, or derivatives; and *CHAG* antisense nucleic acids.

30 Animal models and methods to identify agonists and antagonists of *CHAG* are also provided by the invention.

(1) Definitions

CHAG: cardiac hypertrophy associated genes, identified by the present inventors, including *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, *CH-9*, and *α-Enolase*, *Antizyme Inhibitor*, *Biglycan*, *Cytochrome Oxidase I*, *Cytochrome Oxidase II*, *Cyclin G*, *D-binding protein*, *Desmin*, *Fibrillin*, *Laminin A-1*, *p85* and *Preproenkephalin*, *Protein Kinase C-Binding Protein β15* and genes encoding 5.8S, 18S and 28S rRNAs.

CH: novel cardiac hypertrophy genes including: *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8* and *CH-9*.

QEA®: Quantitative Expression Analysis.

DESCRIPTION OF THE FIGURES

In order that the present invention disclosed herein is better understood and appreciated, the following detailed description is set forth.

Figure 1: Gene expression assayed by QEA and Northern analysis. Twenty two genes were identified by QEA as being differentially expressed in Pressure Overload (POL) hearts. The graph depicts the relative increase (+ values) or decrease (-values) in levels of gene expression averaged between the POL and unoperated hearts and the POL and sham operated hearts. Gray bars indicate the relative expression values as determined by QEA, black bars indicate the relative expression values as determined by Northern analysis.

Figure 2: (Panel A) - The nucleotide sequence of *CH-1* [SEQ ID NO:1]; (Panel B) - Comparison with the nucleotide sequence of the mouse *amyloid beta-peptide binding protein* and (Panel C) - Comparison with the nucleotide sequence of the human *short-chain alcohol dehydrogenase*.

Figure 3: (Panel A) - The nucleotide sequence of *CH-2* [SEQ ID NO:2] and (Panel B) - Comparison with the nucleotide sequence of mouse *α-1 Collagen Type III*.

Figure 4: (Panel A) - The nucleotide sequence of *CH-3* [SEQ ID NO:3] and (Panel B) - Comparison with the nucleotide sequence of mouse *α-1 Collagen Type IV*.

Figure 5: (Panel A) - The nucleotide sequence of *CH-4* [SEQ ID NO:4] and (Panel B) - Comparison with the nucleotide sequence of human *Collagen Type XIV*.

5 Figure 6: (Panel A) - The nucleotide sequence of *CH-5* [SEQ ID NO:5] and (Panel B) - Comparison with the human *13kD DAP*.

Figure 7: (Panel A) - The nucleotide sequence of *CH-6* [SEQ ID NO:6] and (Panel B) - Comparison with the nucleotide sequence of mouse *Gelsolin*.

10

Figure 8: (Panel A) - The nucleotide sequence of *CH-7* [SEQ ID NO:7] and (Panel B) - Comparison with the nucleotide sequence of rat *Osteonectin*.

Figure 9: (Panel A) - The nucleotide sequence of *CH-8* [SEQ ID NO:8] and (Panel B) - Comparison with the nucleotide sequence of mouse *Transglutaminase*.

15

Figure 10: (Panel A) - The nucleotide sequence of *CH-8* [SEQ ID NO:9] and (Panel B) - Comparison with the nucleotide sequence of mouse *Zyxin*.

20 Table 1: Lists the novel genes which were identified by the QEA methodology in hypertrophic cardiac tissue.

Table 2: Lists the previously-characterized genes which were identified by the QEA methodology in hypertrophic cardiac tissue.

DETAILED DESCRIPTION OF THE INVENTION

The present inventors have applied quantitative expression analysis to a rat surgical model of cardiac hypertrophy (RCH) which results in a 60% increase in ventricle mass. The present inventors discovered that the expression level of a number of known genes, not previously associated with cardiac hypertrophy, is significantly altered in the surgical model of cardiac hypertrophy. The inventors have also identified nine novel genes, defined as *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, and *CH-9*, that have nucleotide sequence homology to, but are not identical to, the human *short-chain alcohol dehydrogenase* and mouse *amyloid beta-peptide binding protein*, mouse α -1 *Collagen Type III*, mouse α -1 *Collagen Type IV*, chicken *Collagen Type XIV*, human *13kD DAP*, mouse and human *Gelsolin*, mouse *Osteonectin*, mouse *Transglutaminase*, and mouse and human *Zyxin*, respectively. Other genes identified in the present invention include α -*Enolase*, *Antizyme Inhibitor*, *Biglycan*, *Cytochrome Oxidase I*, *Cytochrome Oxidase II*, *Cyclin G*, *Rat D-binding protein*, *Desmin*, *Fibrillin*, *Laminin α -1*, *p85*, *Preproenkephalin*, *Protein Kinase C-Binding Protein β 15* and genes encoding 5.8S, 18S and 28S rRNAs. *CH-1*, *Desmin*, *Protein Kinase C-Binding Protein β 15* and genes encoding 5.8S, 18S and 28S rRNAs are down-regulated in hypertrophic cardiac tissues compared to controls. *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, *CH-9*, and α -*Enolase*, *Antizyme Inhibitor*, *Biglycan*, *Cytochrome Oxidase I*, *Cytochrome Oxidase II*, *Cyclin G*, *Rat D-binding protein*, *Fibrillin*, *Laminin α -1*, *p85* and *Preproenkephalin* are up-regulated in hypertrophic cardiac tissues compared to controls.

Accordingly, the present invention provides the nucleotide sequences of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, and *CH-9*, and the amino acid sequence of the proteins encoded by these genes. The invention further relates to the proteins, derivatives, fragments and homologs thereof, as well as nucleic acids encoding the above-listed proteins, derivatives, fragments and homologs. The invention provides the above-listed proteins and genes encoding these proteins of many different species, particularly vertebrates, and more particularly mammals. In a preferred embodiment, the above-listed proteins and genes are of human origin. Production of the foregoing proteins and derivatives, *e.g.* by recombinant methods, is provided.

The invention also provides derivatives and analogs of the above-listed proteins which are functionally active, *i.e.*, capable of displaying one or more known functional activities associated with a full length (wild-type) protein selected from the group consisting of the above-listed proteins. Such functional activities include, but are not limited to, antigenicity [ability to

bind (or compete with the above-listed proteins for binding) to an antibody to the above-listed proteins, respectively], immunogenicity (ability to generate an antibody that binds to the above-listed proteins), etc.

Antibodies to proteins encoded by *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*,
5 and *CH-9*, and derivatives and analogs thereof, are additionally provided.

The present invention further relates to therapeutic and diagnostic methods and compositions based on CHAG proteins and nucleic acids. The invention provides for treatment of cardiac hypertrophy by administering compounds that modulate (i.e. promote, antagonize or inhibit) CHAG protein activity (e.g., CHAG proteins and functionally active analogs and
10 derivatives (including fragments) thereof; nucleic acids encoding the CHAG proteins, analogs, or derivatives, agonists of CHAG proteins).

Animal models, diagnostic methods and screening methods for predisposition to cardiac hypertrophy are also provided by the invention.

For clarity of disclosure, and not by way of limitation, the detailed description of the
15 invention is divided into the subsections which follow.

(1) CHAG Proteins and Derivatives and Analogs

The invention relates to CHAG proteins as well as derivatives (including but not limited to fragments) and homologs and paralogs of CHAG proteins. In one embodiment human CHAG
20 genes and proteins are provided. In specific aspects, the native proteins, fragments, derivatives or analogs of CHAG are of animals, e.g. mouse, rat, chicken, or human. In other specific embodiments, the fragment, derivative or analog is functionally active, i.e., capable of exhibiting one or more functional activities associated with full-length, wild-type CHAG, e.g., immunogenicity or antigenicity.

25 The nucleotide sequences encoding, and the corresponding amino acid sequences, of rat α -Enolase (GenBank Accession No. H35207), Antizyme Inhibitor (GenBank Accession No. D50734), Biglycan (GenBank Accession No. U17834), Cytochrome Oxidase I (GenBank Accession No. J01435), Cytochrome Oxidase II (GenBank Accession No. J01434), Cyclin G (GenBank Accession No. X70871), D-binding protein (GenBank Accession No. J03179),
30 Desmin (GenBank Accession No. X73524), Fibrillin (GenBank Accession No. L19896), Laminin α -1 (GenBank Accession No. X94551), Protein kinase C-binding protein α 15 (GenBank Accession No. U48248), p85 (GenBank Accession No. U42581), 5.8S-18S-28S rRNAs (GenBank Accession No. V01272), Preproenkephalin (GenBank Accession No.

K02805), and human 28S rRNA (GenBank Accession No. M11167), are known. Partial nucleic acid sequences of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, and *CH-9* are disclosed in Figures 2-10, respectively. Complete nucleic acids of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, and *CH-9* can be obtained by any method known in the art, *e.g.*, by PCR
5 amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence and/or by cloning from a cDNA or genomic library using a PCR amplification product or an oligonucleotide specific for the gene sequence (*e.g.*, as described in Section 5.2, *infra*).
Homologs (*e.g.*, nucleic acids of the above-listed genes of species other than rat) or other related sequences (*e.g.*, paralogs) can be obtained by low, moderate or high stringency hybridization
10 with all or a portion of the particular sequence provided as a probe using methods well known in the art for nucleic acid hybridization and cloning (*e.g.*, as described in Section 5.2, *infra*, for nucleic acids of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, and *CH-9*).

The CHAG proteins can be obtained by methods well known in the art for protein purification and recombinant protein expression. For recombinant expression of one or more of
15 the proteins, the nucleic acid containing all or a portion of the nucleotide sequence encoding the protein can be inserted into an appropriate expression vector, *i.e.*, a vector that contains the necessary elements for the transcription and translation of the inserted protein coding sequence. The necessary transcriptional and translational signals can also be supplied by the native promoter for CHAG genes, and/or their flanking regions.

20 A variety of host-vector systems may be utilized to express the protein coding sequence. These include but are not limited to mammalian cell systems infected with virus (*e.g.* vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.* baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary
25 in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Any of the methods described in Section 5.2 *infra*, for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and protein coding sequences. These
30 methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequences encoding CHAG, or derivatives, fragments or homologs thereof, may be regulated by a second nucleic acid sequence so that the genes or fragments thereof are expressed in a host transformed with the

recombinant DNA molecule(s). For example, expression of the proteins may be controlled by any promoter/enhancer known in the art. In a specific embodiment, the promoter is not native to the genes for CHAG. Promoters which may be used include but are not limited to the SV40 early promoter (Bernoist and Chambon, *Nature* 290:304-310 (1981)), the promoter contained in the 3'-long terminal repeat (LTR) of Rous sarcoma virus (Yamamoto *et al.*, *Cell* 22:787-797 (1980)), the herpes thymidine kinase promoter (Wagner *et al.*, *Proc. Natl. Acad. Sci. USA* 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster *et al.*, *Nature* 296:39-42 (1982)); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff *et al.*, *Proc. Natl. Acad. Sci. USA* 75:3727-3731 (1978)) or the *tac* promoter (DeBoer *et al.*, *Proc. Natl. Acad. Sci. USA* 80:21-25 (1983)); see also A Useful Proteins from Recombinant Bacteria: in Scientific American 242:79-94 (1980)); plant expression vectors comprising the nopaline synthetase promoter (Herrar-Estrella *et al.*, *Nature* 303:209-213 (1984)) or the cauliflower mosaic virus 35S RNA promoter (Gardner *et al.*, *Nucleic Acids Res.* 9:2871 (1981)), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella *et al.*, *Nature* 310:115-120 (1984)); promoter elements from yeast and other fungi such as the Gal4 promoter, the alcohol dehydrogenase promoter, the phosphoglycerol kinase promoter, the alkaline phosphatase promoter, and the following animal transcriptional control regions that exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift *et al.*, *Cell* 38:639-646 (1984); Ornitz *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409 (1986); MacDonald, *Hepatology* 7:425-515 (1987)); insulin gene control region which is active in pancreatic beta cells (Hanahan *et al.*, *Nature* 315:115-122 (1985)), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl *et al.*, *Cell* 38:647-658 (1984); Adams *et al.*, *Nature* 318:533-538 (1985); Alexander *et al.*, *Mol. Cell Biol.* 7:1436-1444 (1987)), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder *et al.*, *Cell* 45:485-495 (1986)), albumin gene control region which is active in liver (Pinckert *et al.*, *Genes and Devel.* 1:268-276 (1987)), alpha-fetoprotein gene control region which is active in liver (Krumlauf *et al.*, *Mol. Cell. Biol.* 5:1639-1648 (1985); Hammer *et al.*, *Science* 235:53-58 (1987)), α -1 antitrypsin gene control region which is active in liver (Kelsey *et al.*, *Genes and Devel.* 1:161-171 (1987)), beta globin gene control region which is active in myeloid cells (Mogram *et al.*, *Nature* 315:338-340 (1985); Kollias *et al.*, *Cell* 46:89-94 (1986)), myelin basic protein gene control region which is active in oligodendrocyte cells of the brain (Readhead *et al.*, *Cell* 48:703-712 (1987)), myosin light chain-2 gene control region which is

active in skeletal muscle (Sani. *Nature* 314:283-286 (1985)). and gonadotrophic releasing hormone gene control region which is active in gonadotrophs of the hypothalamus (Mason *et al.*, *Science* 234:1372-1378 (1986)).

5 In a specific embodiment, a vector is used that comprises a promoter operably linked to nucleic acid sequences encoding CHAG, or a fragment, derivative or homolog, thereof, one or more origins of replication, and optionally, one or more selectable markers (*e.g.*, an antibiotic resistance gene).

10 In another specific embodiment, an expression vector containing the coding sequences, or portions thereof, of CHAG, is made by subcloning the gene sequences into the EcoRI restriction site of each of the three pGEX vectors (glutathione S-transferase expression vectors (Smith and Johnson, *Gene* 7:31-40 (1988)). This allows for the expression of gene products in the correct reading frame.

15 Expression vectors containing the sequences of interest can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of a marker of gene function, and (c) expression of the inserted sequences. In the first approach, *CHAG* sequences can be detected by nucleic acid hybridization to probes comprising sequences homologous and complementary to the inserted sequences. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain marker functions (*e.g.*, binding to an anti-CHAG antibody, resistance to antibiotics, occlusion body formation in baculovirus, etc.) caused by insertion of the sequences of interest in the vector. For example, if a *CHAG* gene, or portion thereof, is inserted within the marker gene sequence of the vector, recombinants containing the *CHAG* fragment will be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by 25 assaying for the CHAG, or other CHAG products expressed by the recombinant vector. Such assays can be based, for example, on the physical or functional properties of the interacting species in *in vitro* assay systems, *e.g.*, activation of T cell, immunoreactivity to antibodies specific for the protein.

30 Once recombinant *CHAG* molecules are identified and the proteins isolated, several methods known in the art can be used to propagate them. Once a suitable host system and growth conditions have been established, recombinant expression vectors can be propagated and amplified in quantity. As previously described, the expression vectors or derivatives which can be used include, but are not limited to: human or animal viruses such as vaccinia virus or

adenovirus; insect viruses such as baculovirus, yeast vectors; bacteriophage vectors such as lambda phage; and plasmid and cosmid vectors.

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies or processes the expressed proteins in the specific fashion desired.

5 Expression from certain promoters can be elevated in the presence of certain inducers; thus expression of the genetically-engineered CHAG may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (*e.g.* glycosylation, phosphorylation, etc.) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the
10 foreign protein is achieved. For example, expression in a bacterial system can be used to produce an unglycosylated core protein, while expression in mammalian cells ensures native glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extent.

In other specific embodiments, the CHAG or fragments, homologs or derivatives thereof,
15 may be expressed as fusion or chimeric protein products comprising the protein, fragment, homolog, or derivative joined via a peptide bond to a heterologous protein sequence of a different protein. Such chimeric products can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acids to each other by methods known in the art, in the proper coding frame, and expressing the chimeric products in a suitable host by methods
20 commonly known in the art. Alternatively, such a chimeric product can be made by protein synthetic techniques, *e.g.*, by use of a peptide synthesizer. Chimeric genes comprising portions of CHAG fused to any heterologous protein-encoding sequences may be constructed. A specific embodiment relates to a chimeric protein comprising a fragment of CHAG of at least 6 amino acids.

25 In particular, CHAG derivatives can be made by altering their sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a *CHAG* gene can be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of *CHAG* genes
30 that are altered by the substitution of different codons that encode the amino acid residue within the sequence, thus producing a silent change. Likewise, the CHAG derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of CHAG, including altered sequences in which functionally equivalent

amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other
5 members of the class to which the amino acid belongs. For example, the non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include
10 aspartic acid and glutamic acid.

In a specific embodiment of the invention, the nucleic acids encoding proteins and proteins consisting of or comprising a fragment of CHAG consisting of at least 6 (continuous) amino acids of CHAG are provided. In other embodiments, the fragment consists of at least 10, 20, 30, 40, or 50 amino acids of CHAG. In specific embodiments, such fragments are not larger
15 than 35, 100 or 200 amino acids. Derivatives or analogs of CHAG include but are not limited to molecules comprising regions that are substantially homologous to CHAG in various embodiments, at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% identity over an amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art or whose encoding nucleic acid is
20 capable of hybridizing to a sequence encoding CHAG under stringent, moderately-stringent, or non-stringent conditions.

The CHAG derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned *CHAG* gene sequence can be modified by any of
25 numerous strategies known in the art (Sambrook *et al.*, 1990, *Molecular Cloning, A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The sequences can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding a derivative or analog of CHAG, care should be taken to ensure that the modified
30 gene retains the original translational reading frame, uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

Additionally, the CHAG-encoding nucleotide sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create

variations in coding regions and/or form new restriction endonuclease sites or destroy pre-existing ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including but not limited to, chemical mutagenesis and *in vitro* site-directed mutagenesis (Hutchinson *et al.*, *J. Biol. Chem.* 253:6551-6558 (1978)), use of TAB7 linkers
5 (Pharmacia), etc.

Once a recombinant cell expressing a CHAG protein, or fragment or derivative thereof, is identified, the individual gene product can be isolated and analyzed. This is achieved by assays based on the physical and/or functional properties of the protein, including, but not limited to, radioactive labeling of the product followed by analysis by gel electrophoresis, immunoassay,
10 cross-linking to marker-labeled product, etc.

The CHAG proteins may be isolated and purified by standard methods known in the art (either from natural sources or recombinant host cells expressing the complexes or proteins), including but not restricted to column chromatography (*e.g.*, ion exchange, affinity, gel exclusion, reversed-phase high pressure, fast protein liquid, etc.), differential centrifugation,
15 differential solubility, or by any other standard technique used for the purification of proteins. Functional properties may be evaluated using any suitable assay known in the art.

Alternatively, once a CHAG or its derivative is identified, the amino acid sequence of the protein can be deduced from the nucleotide sequence of the gene which encodes it. As a result, the protein or its derivative can be synthesized by standard chemical methods known in the art
20 (*e.g.* see Hunkapiller *et al.*, *Nature* 310:105-111 (1984)).

Manipulations of CHAG sequences may be made at the protein level. Included within the scope of the invention are CHAG derivatives or analogs or fragments, which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic
25 cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, etc.

30 In specific embodiments, the CHAG sequences are modified to include a fluorescent label. In another specific embodiment the CHAG is modified to have a heterofunctional reagent, such heterofunctional reagents can be used to cross-link the members of the complex.

In addition, analogs and derivatives of a CHAG can be chemically synthesized. For

example, a peptide corresponding to a portion of a CHAG, which comprises the desired domain or which mediates the desired activity *in vitro* can be synthesized by use of a peptide synthesizer. Furthermore, if desired, non-classical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the CHAG sequence. Non-classical amino acids include, but are not limited to the D-isomers of the common amino acids, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-aminobutyric acid, α -Abu, ϵ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoro-amino acids, designer amino acids such as β -methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids, and amino acid analogs in general.

In cases where natural products are suspected of being mutant or are isolated from new species, the amino acid sequence of the CHAG isolated from the natural source, as well as those expressed *in vitro*, or from synthesized expression vectors *in vivo* or *in vitro*, can be determined from analysis of the DNA sequence, or alternatively, by direct sequencing of the isolated protein. Such analysis may be performed by manual sequencing or through use of an automated amino acid sequenator.

The CHAG proteins may also be analyzed by hydrophilicity analysis (Hopp and Woods, *Proc. Natl. Acad. Sci. USA* 78:3824-3828 (1981)). A hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the proteins, and help predict their orientation in designing substrates for experimental manipulation, such as in binding experiments, antibody synthesis, etc. Secondary structural analysis can also be done to identify regions of the CHAG that assume specific structures (Chou and Fasman, *Biochemistry* 13:222-23 (1974)). Manipulation, translation, secondary structure prediction, hydrophilicity and hydrophobicity profiles, open reading frame prediction and plotting, and determination of sequence homologies, can be accomplished using computer software programs available within the art.

Other methods of structural analysis including but not limited to X-ray crystallography (Engstrom, *Biochem. Exp. Biol.* 11:7-13 (1974)), mass spectroscopy and gas chromatography (Methods in Protein Science, J. Wiley and Sons, New York, 1997), and computer modeling (Fletterick and Zoller, eds., 1986, Computer Graphics and Molecular Modeling. In: *Current Communications in Molecular Biology*. Cold Spring Harbor Laboratory, Cold Spring Harbor Press, New York) can also be employed.

(2) Identification and Isolation of CH Genes

The invention relates to the nucleotide sequences of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, and *CH-9*. In specific embodiments, the CH nucleic acids comprise the sequence of SEQ ID NOS:1-9 respectively, (as depicted in Figures 2A-10A, respectively) or the coding regions thereof, or nucleotide sequences encoding, in whole or in part, a CH protein. The invention provides purified nucleic acids consisting of at least 8 nucleotides (*i.e.*, a hybridizable portion) of a *CH* sequence; in other embodiments, the nucleic acids consist of at least 25 (continuous) nucleotides, 50 nucleotides, 100 nucleotides, 150 nucleotides, or 200 nucleotides of a *CH* sequence, or a full-length CH coding sequence. In another embodiment, the nucleic acids are smaller than 35, 200 or 500 nucleotides in length. Nucleic acids can be single or double stranded. The invention also relates to nucleic acids hybridizable to or complementary to the foregoing sequences, in particular the invention provides the inverse complement to nucleic acids hybridizable to the foregoing sequences (*i.e.* the inverse complement of a nucleic acid strand has the complementary sequence running in reverse orientation to the strand so that the inverse complement would hybridize without mismatches to the nucleic acid strand; thus, for example, where the coding strand is hybridizable to a nucleic acid with no mismatches between the coding strand and the hybridizable strand, then the inverse complement of the hybridizable strand is identical to the coding strand). In specific aspects, nucleic acids are provided which comprise a sequence complementary to (specifically are the inverse complement of) at least 10, 25, 50, 100, or 200 nucleotides or the entire coding region of a *CH* gene.

In a specific embodiment, a nucleic acid which is hybridizable to a *CH* nucleic acid (*e.g.*, having a sequence of SEQ ID NOS:1-9, respectively), or to a nucleic acid encoding a CH derivative, under conditions of low stringency is provided. By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also Shilo and Weinberg, *Proc. Natl. Acad. Sci. USA* 78:6789-6792 (1981)): Filters containing DNA are pretreated for 6 hours at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 x 10⁶ cpm ³²P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 hours at 40°C, and then washed for 1.5 hours at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60°C. Filters are

blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and re-exposed to film. Other conditions of low stringency which may be used are well known in the art (*e.g.*, as employed for cross-species hybridizations).

5 In another specific embodiment, a nucleic acid which is hybridizable to a *CH* nucleic acid under conditions of high stringency is provided. By way of example and not way of limitation, procedures using such conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in prehybridization
10 mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 x 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 minutes before autoradiography. Other conditions of high stringency which may be used are well-known within the art.

15 In another specific embodiment, a nucleic acid, which is hybridizable to a *CH* nucleic acid under conditions of moderate stringency is provided. For example, but not limited to, procedures using such conditions of moderate stringency are as follows: Filters containing DNA are pretreated for 6 hours at 55°C in a solution containing 6X SSC, 5X Denhart's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same
20 solution and 5-20 x 10⁶ cpm ³²P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 hours at 55°C, and then washed twice for 30 minutes at 60°C in a solution containing 1X SSC and 0.1% SDS. Filters are blotted dry and exposed for autoradiography. Other conditions of moderate stringency which may be used are well-known in the art. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.1% SDS.

25 Nucleic acids encoding derivatives and analogs of *CH* proteins and *CH* antisense nucleic acids are additionally provided. As is readily apparent, as used herein, a "nucleic acid encoding a fragment or portion of a *CH*" shall be construed as referring to a nucleic acid encoding only the recited fragment or portion of *CH* protein, and not the other contiguous portions of the *CH* as a continuous sequence.

30 Fragments of *CH* nucleic acids comprising regions conserved between (with homology to) other *CH* nucleic acids, of the same or different species, are also provided.

Any method available in the art can be used to obtain a full length (*i.e.*, encompassing the entire coding region) cDNA or genomic DNA clone encoding a *CH*. In particular, the

polymerase chain reaction (PCR) can be used to amplify a sequence identified as being differentially expressed in hypertrophic cardiac tissue, e.g. nucleic acids comprising the nucleotide sequences of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8* and *CH-9* (SEQ. NOS: 1-9 respectively), in a genomic or cDNA library. Oligonucleotide primers that hybridize to sequences at the 3'- and 5'-termini of the identified sequences can be used as primers to amplify by PCR sequences from a nucleic acid sample (RNA or DNA), preferably a cDNA library, from an appropriate source (e.g. hypertrophic cardiac tissue).

PCR can be carried out, e.g., by use of a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp®). The DNA being amplified can include mRNA or cDNA or genomic DNA from any eukaryotic species. One can choose to synthesize several different degenerate primers, for use in the PCR reactions. It is also possible to vary the stringency of hybridization conditions used in priming the PCR reactions, to amplify nucleic acid homologs (e.g. to obtain *CH* sequences from species other than humans or to obtain human sequences with homology to *CH*) by allowing for greater or lesser degrees of nucleotide sequence similarity between the known nucleotide sequence and the nucleic acid homolog being isolated. For cross species hybridization, low stringency conditions are preferred. For same species hybridization, moderately stringent conditions are preferred.

After successful amplification of the nucleic acid containing all or a portion of the identified *CH* sequence or of a nucleic acid encoding all or a portion of a *CH* homolog, that segment may be molecularly cloned and sequenced, and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, will permit the determination of the gene's complete nucleotide sequence, the analysis of its expression, and the production of its protein product for functional analysis, as described *infra*. Once the nucleotide sequence is determined, an open reading frame encoding the *CH* gene protein product can be determined by any method well known in the art for determining open reading frames, for example, using publicly available computer programs for nucleotide sequence analysis. Once an open reading frame is defined, it is routine to determine the amino acid sequence of the protein encoded by the open reading frame. In this way, the amino acid sequences of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8* and *CH-9* can be determined from the nucleotide sequences of the corresponding genes. Thus, the nucleotide sequences of the entire *CH* genes as well as the amino acid sequences of *CH* proteins and analogs may be identified.

Any eukaryotic cell potentially can serve as the nucleic acid source for the molecular cloning of the *CH* gene. The nucleic acids can be isolated from vertebrate, mammalian, human,

porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, insects, plants, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example, Sambrook *et al.*, 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K. Vol. I, II). Clones derived from genomic DNA may contain regulatory and intronic DNA regions in addition to coding regions; clones derived from cDNA will contain only exonic sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired gene may be accomplished in a number of ways. For example, a portion of the *CH* (of any species) gene (e.g., a PCR amplification product obtained as described above or an oligonucleotide having a sequence of a portion of the known nucleotide sequence) or its specific RNA, or a fragment thereof be purified and labeled, and the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton and Davis, *Science* 196:180 (1977); Grunstein and Hogness, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961 (1975)). Those DNA fragments with substantial homology to the probe will hybridize. It is also possible to identify the appropriate fragment by restriction enzyme digestion(s) and comparison of fragment sizes with those expected according to a known restriction map if such is available or by DNA sequence analysis and comparison to the known nucleotide sequence of *CH*. Further selection can be carried out on the basis of the properties of the gene. Alternatively, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, e.g., has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, or antigenic properties or ability to activate T cell, as known for the *CH*. If an anti-*CH* antibody is available,

the protein may be identified by binding of labeled antibody to the putatively CH synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure.

Alternatives to isolating the *CH* genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA
5 that encodes the CH protein. For example, RNA for cDNA cloning of the *CH* gene can be isolated from cells expressing the protein. Other methods are possible and within the scope of the invention.

The identified and isolated nucleic acids can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors
10 include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene, La Jolla, CA). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has
15 complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition
20 sequences. In an alternative method, the cleaved vector and *CH* gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion
25 into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated *CH* gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing
30 transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The *CH* sequences provided by the instant invention include those nucleotide sequences encoding substantially the same amino acid sequences as found in native CH proteins, and those

encoded amino acid sequences with functionally equivalent amino acids, as well as those encoding other CH derivatives or analogs, as described in Section 5.1 *supra* for CH derivatives and analogs.

(2) Antibodies to CH Proteins

5 According to the invention, the CH protein and fragments, homologs and derivatives thereof may be used as immunogens to generate antibodies which immunospecifically bind such immunogens. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. In a specific embodiment, antibodies to human CH are produced. In another embodiment, complexes formed from fragments of CH,
10 which fragments contain the protein domain that interacts with and activates T cell, are used as immunogens for antibody production.

Various procedures known in the art may be used for the production of polyclonal antibodies to CH protein, derivatives, fragments or analogs.

For production of the antibody, various host animals can be immunized by injection with
15 the native CH protein or a synthetic version, or a derivative of the foregoing, such as a cross-linked CH, such host animals include but are not limited to rabbits, mice, rats, etc. Various adjuvants can be used to increase the immunological response, depending on the host species, and include but are not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols,
20 polyanions, peptides, oil emulsions, dinitrophenol, and potentially useful human adjuvants such as *bacille Calmette-Guerin* (BCG) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed towards a CH or derivatives, fragments or analogs thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. Such techniques include but are not restricted to the
25 hybridoma technique originally developed by Kohler and Milstein (*Nature* 256:495-497 (1975)), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* 4:72 (1983)), and the EBV hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free
30 animals utilizing recent technology (PCT/US90/02545). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote *et al.*, *Proc. Natl. Acad. Sci. USA* 80:2026-2030 (1983)). Or by transforming human B cells with EBV virus *in vitro* (Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96

(1985)). In fact, according to the invention, techniques developed for the production of Achimeric antibodies (Morrison *et al.*, *Proc. Natl. Acad. Sci. USA* 81:6851-6855 (1984); Neuberger *et al.*, *Nature* 312:604-608 (1984); Takeda *et al.*, *Nature* 314:452-454 (1985)) by splicing the genes from a mouse antibody molecule specific for the CH protein together with
5 genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention.

According to the invention, techniques described for the production of single chain antibodies (U.S. patent 4,946,778) can be adapted to produce CH-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the
10 construction of Fab expression libraries (Huse *et al.*, *Science* 246:1275-1281 (1989)) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for CH or CH derivatives, or analogs thereof. Non-human antibodies can be "humanized" by known methods (*see, e.g.*, U.S. Patent No. 5,225,539).

Antibody fragments that contain the idiotypes of CH can be generated by techniques
15 known in the art. For example, such fragments include but are not limited to: the F(ab)₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab fragments that can be generated by reducing the disulfide bridges of the F(ab)₂ fragment, the Fab fragments that can be generated by treating the antibody molecular with papain and a reducing agent, and Fv fragments.

20 In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.*, ELISA (enzyme-linked immunosorbent assay). To select antibodies specific to a particular domain of the CH one may assay generated hybridomas for a product that binds to the fragment of the CH that contains such a domain

Antibodies to specific domains of CH are also provided.

25 The foregoing antibodies can be used in methods known in the art relating to the localization and/or quantitation of CH proteins of the invention, *e.g.*, for imaging these proteins, measuring levels thereof in appropriate physiological samples, in diagnostic methods, etc.

In another embodiment of the invention (*see infra*), anti-novel-CHAG antibodies, or fragments thereof, containing the binding domain are Therapeutics.

30

(3) Methods of Treatment

The present invention provides methods of treating and preventing cardiac hypertrophy diseases and disorders by administration of a therapeutic compound (termed herein

"Therapeutic") of the invention. In one aspect of the invention, such "Therapeutics" include CHAG proteins and analogs, derivatives and fragments thereof (*e.g.*, as described hereinabove) and nucleic acids encoding CHAG proteins, analogs, derivatives, or fragments (*e.g.*, as described hereinabove), anti-CHAG antibodies, *CHAG* anti-sense nucleic acids, and modulators (*i.e.*,
5 agonists, antagonists and inhibitors) of *CHAG*.

The subject to which the Therapeutic is administered is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal. In a preferred embodiment, the subject is a human.

Generally, administration of products of a species origin or species reactivity (in the case
10 of antibodies) that is the same species as that of the subject is preferred. Thus, in a preferred embodiment, a human CHAG protein, derivative, or analog, or nucleic acid, is therapeutically or prophylactically administered to a human patient.

The CHAG protein, derivative, or analog, or nucleic acid, or modulator of CHAG protein or nucleic acid, of the invention can be assayed by any of the methods described *infra* to
15 determine whether increasing or decreasing activities of CHAG proteins or nucleic acids will treat or prevent cardiac hypertrophy. In the event it is determined that decreasing activities of a CHAG protein or nucleic acid will treat or prevent cardiac hypertrophy, then molecules that inhibit activities of CHAG proteins or nucleic acids, such as anti-CHAG antibodies, *CHAG* anti-sense nucleic acids, CHAG antagonists or inhibitors, are envisioned for use to treat or prevent
20 cardiac hypertrophy, preferably pressure overload cardiac hypertrophy.

Accordingly, in a specific embodiment of the invention, CHAG antagonists and inhibitors, including but not limited to anti-CHAG antibodies (*e.g.* as described below) and *CHAG* anti-sense nucleic acids (*e.g.* as described below) and CHAG derivatives (*e.g.*, that are competitive inhibitors of CHAG) are administered to treat or prevent cardiac hypertrophy,
25 preferably pressure overload cardiac hypertrophy.

Alternatively, in the event it is determined that increasing the activity of a CHAG protein or nucleic acid will treat or prevent cardiac hypertrophy, CHAG proteins or nucleic acids and molecules that enhance CHAG activity are also envisioned for use to treat or prevent cardiac hypertrophy, preferably pressure overload cardiac hypertrophy.

30 Accordingly, in a specific embodiment of the invention, CHAG protein, nucleic acids or molecules that enhance CHAG activity are administered to treat or prevent cardiac hypertrophy, preferably pressure overload cardiac hypertrophy.

(4) Cardiac Hypertrophic Disease

In a preferred embodiment, Therapeutics of the invention are administered therapeutically, and preferably, prophylactically, to patients suffering from or in danger of suffering from cardiac hypertrophy disease, preferably pressure overload cardiac hypertrophy, have previously suffered a systematic hypertension or aortic stenosis event, or exhibit one or more "risk factors" for cardiac hypertrophy (*i.e.*, a characteristic, behavior or disorder correlated with increased incidence of cardiac hypertrophy) or one or more conditions associated with cardiac hypertrophy. See Hutter, Jr., "Congestive Heart Failure", in Scientific American: Medicine, Volume 1 (1:II), eds. Dale and Federman (Scientific American, Inc. 1994) and "Hypertrophic Cardiomyopathy", in The Merck Manual of Diagnosis and Therapy, Chapter 27, p519-522, eds. Berkow *et al.*, (Merck Sharp & Dohme Research Laboratories 1987).

Major indications of predisposition for cardiac hypertrophy predisposition are chest pains, syncope, palpitations, effort dyspnea or symptoms of aortic stenosis or coronary artery disease, or any combination the foregoing indications. Chest pain is usually typical angina related to exertion. Syncope is usually exertional, due to a combination of arrhythmia, outflow tract obstruction, and diastolic filling of the ventricle. Dyspnea on exertion is a result of poor diastolic compliance of the left ventricle that leads to rapid rise in LVEDP as flow increases. Palpitations are produced by ventricle or atrial arrhythmias.

Patients suffering from heart failure may also be predisposed to cardiac hypertrophy. By way of example but not by way of limitation, coronary artery disease, cardiomyopathy, myocarditis, aortic stenosis, hypertension, coarctation of the aorta, aortic regurgitation, mitral regurgitation, left-to-right shunts, restrictive cardiomyopathy, ischemic heart disease, pericardial tamponade, constrictive pericarditis, or restrictive cardiomyopathy can increase the likelihood that a patient will suffer a cardiac hypertrophy.

Therapeutics of the invention may also be administered with drugs which treat or ameliorate the effect of certain risk factors for cardiac hypertrophy. In a preferred embodiment, a Therapeutic of the invention is administered with one or more anti-cardiac-hypertrophy drug such as, but not limited to, β -Adrenoceptor blockers and Ca^{2+} -channel blockers, or carried out in conjunction with anti-arrhythmic therapy, antibiotic prophylaxis, or surgical treatment in the form of septal myotomy, myomectomy, or mitral valve replacement.

It is within the skill of those in the art to monitor and adjust the treatment or prophylactic regimen for treating or preventing cardiac hypertrophy disease while treating or preventing other potentially associated diseases or disorders, such as systematic hypertension.

(5) Gene Therapy

In a specific embodiment, nucleic acids comprising a sequence encoding a CHAG protein or functional derivative thereof, are administered to promote CHAG protein function, by way of gene therapy. Gene therapy refers to therapy performed by the administration of a nucleic acid to a subject. In this embodiment of the invention, the nucleic acid produces its encoded protein that mediates a therapeutic effect by promoting CHAG protein function.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below. For general reviews of the methods of gene therapy, see Goldspiel *et al.*, *Clinical Pharmacy* 12:488-505 (1993); Wu and Wu, *Biotherapy* 3:87-95 (1991); Tolstoshev, *Ann. Rev. Pharmacol. Toxicol.* 32:573-596 (1993); Mulligan, *Science* 260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); *TIBTECH* 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology are described in Ausubel *et al.*, (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); and Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990).

In a preferred aspect of the present invention, the Therapeutic comprises a CHAG nucleic acid that is part of an expression vector that expresses a CHAG protein or fragment or chimeric protein thereof in a suitable host. In particular, such a nucleic acid has a promoter operably linked to the CHAG coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another particular embodiment, a nucleic acid molecule is used in which the CHAG coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intra-chromosomal expression of the CHAG nucleic acid (Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra *et al.*, *Nature* 342:435-438 (1989)).

Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, cells are first transformed with the nucleic acid *in vitro*, then transplanted into the patient. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene therapy.

In a specific embodiment, the nucleic acid is directly administered *in vivo*, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, *e.g.*, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.*, by infection using a

defective or attenuated retroviral or other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, DuPont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see *e.g.*, Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (see, *e.g.*, PCT Publications WO 92/06180 dated April 16, 1992 (Wu *et al.*); WO 92/22635 dated December 23, 1992 (Wilson *et al.*); WO92/20316 dated November 26, 1992 (Findeis *et al.*); WO93/14188 dated July 22, 1993 (Clarke *et al.*), WO 93/20221 dated October 14, 1993 (Young)). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, *Proc. Natl. Acad. Sci. USA* 86:8932-8935 (1989); Zijlstra *et al.*, *Nature* 342:435-438 (1989)).

In a specific embodiment, a viral vector that contains the *CHAG* nucleic acid is used. For example, a retroviral vector can be used (see Miller *et al.*, *Meth. Enzymol.* 217:581-599 (1993)). These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA. The *CHAG* nucleic acid to be used in gene therapy is cloned into the vector, which facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen *et al.*, *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes *et al.*, *J. Clin. Invest.* 93:644-651 (1994); Kiem *et al.*, *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and

muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout *et al.*, *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of Adenoviruses in gene therapy can be found in Rosenfeld *et al.*, *Science* 252:431-434 (1991); Rosenfeld *et al.*, *Cell* 68:143-155 (1992); and Mastrangeli *et al.*, *J. Clin. Invest.* 91:225-234 (1993).

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh *et al.*, *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993)).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see *e.g.*, Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen *et al.*, *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 (1985)) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. In a preferred embodiment, epithelial cells are injected, *e.g.*, subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (*e.g.*, hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass

any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, *e.g.*, as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient. In another embodiment in which recombinant cells are used in gene therapy, a CHAG nucleic acid is introduced into the cells such that it is expressible by the cells or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained *in vitro* can potentially be used in accordance with this embodiment of the present invention. Such stem cells include but are not limited to hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, liver stem cells (PCT Publication WO 94/08598, dated April 28, 1994), and neural stem cells (Stemple and Anderson, *Cell* 71:973-985 (1992)).

Epithelial stem cells (ESCs) or keratinocytes can be obtained from tissues such as the skin and the lining of the gut by known procedures (Rheinwald, *Meth. Cell Bio.* 21A:229 (1980)). In stratified epithelial tissue such as the skin, renewal occurs by mitosis of stem cells within the germinal layer, the layer closest to the basal lamina. Stem cells within the lining of the gut provide for a rapid renewal rate of this tissue. ESCs or keratinocytes obtained from the skin or lining of the gut of a patient or donor can be grown in tissue culture (Rheinwald, *Meth. Cell Bio.* 21A:229 (1980); Pittelkow and Scott, *Mayo Clinic Proc.* 61:771 (1986)). If the ESCs are provided by a donor, a method for suppression of host versus graft reactivity (*e.g.*, irradiation, drug or antibody administration to promote moderate immunosuppression) can also be used.

With respect to hematopoietic stem cells (HSC), any technique which provides for the isolation, propagation, and maintenance *in vitro* of HSC can be used in this embodiment of the invention. Techniques by which this may be accomplished include, but are not limited to: (a) the isolation and establishment of HSC cultures from bone marrow cells isolated from the future host, or a donor or (b) the use of previously established long-term HSC cultures, which may be allogeneic or xenogeneic. Non-autologous HSC are used preferably in conjunction with a method of suppressing transplantation immune reactions of the future host/patient. In a particular embodiment of the present invention, human bone marrow cells can be obtained from the posterior iliac crest by needle aspiration (see, *e.g.*, Kodo *et al.*, *J. Clin. Invest.* 73:1377-1384

(1984)). In a preferred embodiment of the present invention, the HSCs can be made highly enriched or in substantially pure form. This enrichment can be accomplished before, during, or after long-term culturing, and can be done by any techniques known in the art. Long-term cultures of bone marrow cells can be established and maintained by using, for example, modified
5 Dexter cell culture techniques (Dexter *et al.*, *J. Cell Physiol.* 91:335 (1977) or Witlock-Witte culture techniques (Witlock and Witte, *Proc. Natl. Acad. Sci. USA* 79:3608-3612 (1982)).

In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably-linked to the coding region, such that nucleic acid expression is controllable by the presence or absence of the appropriate inducer of transcription.

10

(6) Therapeutic Utilization of CHAG Antisense Nucleic Acids

In a specific embodiment, as described hereinabove, CHAG function is reduced or inhibited by CHAG antisense nucleic acids, to treat or prevent cardiac hypertrophy, preferably pressure overload cardiac hypertrophy. The present invention provides the therapeutic or
15 prophylactic use of nucleic acids of at least six nucleotides that are antisense to a gene or cDNA encoding CHAG or a portion thereof. An CHAG "antisense" nucleic acid as used herein refers to a nucleic acid capable of hybridizing to a portion of an CHAG RNA (preferably mRNA) by virtue of some sequence complementarity. The antisense nucleic acid may be complementary to a coding and/or noncoding region of an CHAG mRNA. Such antisense nucleic acids have utility
20 as Therapeutics that reduce or inhibit CHAG function, and can be used in the treatment or prevention of disorders as described *supra*.

The CHAG antisense nucleic acids are of at least six nucleotides and are preferably oligonucleotides (ranging from 6 to about 150 nucleotides, or more preferably 6 to 50 nucleotides). In specific aspects, the oligonucleotide is at least 10 nucleotides, at least 15
25 nucleotides, at least 100 nucleotides, or at least 125 nucleotides. The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 84:648-652
30 (1987); PCT Publication No. WO 88/09810, published December 15, 1988) or blood-brain barrier (see, *e.g.*, PCT Publication No. WO 89/10134, published April 25, 1988), hybridization-triggered cleavage agents (see, *e.g.*, Krol *et al.*, *BioTechniques* 6:958-976 (1988)) or intercalating

agents (see, *e.g.*, Zon, *Pharm. Res.* 5:539-549 (1988)).

The *CHAG* antisense nucleic acid is preferably an oligonucleotide, more preferably of single-stranded DNA. In a preferred aspect, the oligonucleotide comprises a sequence antisense to a portion of human CHAG. The oligonucleotide may be modified at any position on its
5 structure with substituents generally known in the art.

The *CHAG* antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine,
10 5-carboxymethylaminomethyluracil, dihydrouracil, β -D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, β -D-mannosylqueosine, 5N-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-
15 isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

In another embodiment, the oligonucleotide comprises at least one modified sugar moiety
20 selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a
25 methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier *et al.*, *Nucl. Acids Res.* 15:6625-6641 (1987)).

30 The oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

Oligonucleotides of the invention may be synthesized by standard methods known in the art, *e.g.* by use of an automated DNA synthesizer (such as are commercially available from

Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein *et al.*, (*Nucl. Acids Res.* 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 85:7448-7451 (1988)), etc.

5 In a specific embodiment, the *CHAG* antisense oligonucleotide comprises catalytic RNA, or a ribozyme (see, *e.g.*, PCT International Publication WO 90/11364, published October 4, 1990; Sarver *et al.*, *Science* 247:1222-1225 (1990)). In another embodiment, the oligonucleotide is a 2N-0-methylribonucleotide (Inoue *et al.*, *Nucl. Acids Res.* 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue *et al.*, *FEBS Lett.* 215:327-330 (1987)).

10 In an alternative embodiment, the *CHAG* antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector can be introduced *in vivo* such that it is taken up by a cell, within which cell the vector or a portion thereof is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the *CHAG* antisense nucleic acid. Such a vector can remain
15 episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the *CHAG* antisense RNA can be by any promoter known in the art to act in mammalian, preferably human,
20 cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, *Nature* 290:304-310 (1981)), the promoter contained in the 3N long terminal repeat of Rous sarcoma virus (Yamamoto *et al.*, *Cell* 22:787-797 (1980)), the herpes thymidine kinase promoter (Wagner *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445 (1981)), the regulatory sequences of the metallothionein gene (Brinster
25 *et al.*, *Nature* 296:39-42 (1982)), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of an *CHAG* gene, preferably a human *CHAG* gene. However, absolute complementarity, although preferred, is not required. A sequence
"complementary to at least a portion of an RNA," as referred to herein, means a sequence having
30 sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded *CHAG* antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer

the hybridizing nucleic acid, the more base mismatches with a an *CHAG* RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

5 The invention further provides pharmaceutical compositions comprising an effective amount of the *CHAG* antisense nucleic acids of the invention in a pharmaceutically acceptable carrier, as described *infra*. In a specific embodiment, pharmaceutical compositions comprising *CHAG* antisense nucleic acids are administered via liposomes, microparticles, or microcapsules. In various embodiments of the invention, it may be useful to use such compositions to achieve
10 sustained release of the *CHAG* antisense nucleic acids.

 The amount of *CHAG* antisense nucleic acid which will be effective in the treatment or prevention of ischemic disease will depend on the nature of the disease, and can be determined by standard clinical techniques. Where possible, it is desirable to determine the antisense cytotoxicity in cells *in vitro*, and then in useful animal model systems prior to testing and use in
15 humans. Additional methods that can be adapted for use to deliver a *CHAG* antisense nucleic acid are described *infra*.

(7) Diagnosis and Screening

CHAG proteins, analogs, derivatives, and subsequences thereof, *CHAG* nucleic acids
20 (and sequences complementary thereto), and anti-*CHAG* antibodies, have uses in diagnostics. Such molecules can be used in assays, such as immunoassays, to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders affecting *CHAG* expression, or monitor the treatment thereof. In particular, such an immunoassay is carried out by a method comprising contacting a sample derived from a patient with an anti-*CHAG* antibody under conditions such
25 that immunospecific binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody. In a specific aspect, such binding of antibody, in tissue sections, can be used to detect aberrant *CHAG* localization or aberrant (*e.g.* low or absent) levels of *CHAG* protein. In a specific embodiment, antibody to *CHAG* protein can be used to assay in a patient tissue or serum sample for the presence of *CHAG* protein where an aberrant level of
30 *CHAG* protein is an indication of a diseased condition. By "aberrant levels," is meant increased or decreased levels relative to that present, or a standard level representing that present, in an analogous sample from a portion of the body or from a subject not having the disorder.

 The immunoassays which can be used include but are not limited to competitive and non-

competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.

CHAG genes and related nucleic acid sequences and subsequences, including complementary sequences, can also be used in hybridization assays. *CHAG* nucleic acid sequences, or subsequences thereof comprising about at least 8 nucleotides, can be used as hybridization probes. Hybridization assays can be used to detect, prognose, diagnose, or monitor conditions, disorders, or disease states associated with aberrant changes in *CHAG* expression and/or activity as described *supra*. In particular, such a hybridization assay is carried out by a method comprising contacting a sample containing nucleic acid with a nucleic acid probe capable of hybridizing to *CHAG* DNA or RNA, under conditions such that hybridization can occur, and detecting or measuring any resulting hybridization.

In specific embodiments, diseases and disorders involving cardiac hypertrophy can be diagnosed, or their suspected presence can be screened for, or a predisposition to develop such disorders can be detected, by detecting decreased levels of *CHAG* genes or proteins that are down-regulated in hypertrophic cardiac tissue, in comparison to normal cardiac tissue (*e.g.* *CH-1*, Desmin, Protein Kinase C-Binding Protein α 15, genes encoding 5.8S, 18S and 28S rRNAs) or *CHAG* functional activity, or by detecting mutations in *CHAG* RNA, DNA or protein (*e.g.* translocations in *CHAG* nucleic acids, truncations in the *CHAG* gene or protein, changes in nucleotide or amino acid sequence relative to wild-type *CHAG*) that cause decreased expression or activity of *CHAG*. Such diseases and disorders include but are not limited to those described in Section 5.4.1. By way of example, levels of *CHAG* protein can be detected by immunoassay, levels of *CHAG* RNA can be detected by QEA or hybridization assays (*e.g.*, Northern blots, dot blots), *CHAG* protein binding to their binding partners can be done by binding assays commonly known in the art, translocations and point mutations in *CHAG* nucleic acids can be detected by Southern blotting, RFLP analysis. PCR using primers that preferably generate a fragment spanning at least most of the *CHAG* gene, sequencing of the *CHAG* genomic DNA or cDNA obtained from the patient, etc.

In another specific embodiment, diseases and disorders involving cardiac hypertrophy, are diagnosed, or their suspected presence can be screened for, or a predisposition to develop such disorders can be detected, by detecting increased levels of *CHAG* proteins or RNA that are

upregulated in hypertrophic cardiac tissue as compared to control tissue (*e.g.*, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, CH-9, α -Enolase, Antizyme Inhibitor, Biglycan, Cytochrome Oxidase I, Cytochrome Oxidase II, Cyclin G, D-binding protein, Fibrillin, Laminin α -1, p85, and Preproenkephalin protein) or CHAG functional activity. or by detecting mutations in CHAG
5 RNA, DNA or protein (*e.g.*, translocations in *CHAG* nucleic acids, truncations in the gene or protein, changes in nucleotide or amino acid sequence relative to wild-type CHAG) that cause increased expression or activity of CHAG. Such diseases and disorders include but are not limited to those described in *infra*. By way of example, levels of CHAG protein, levels of CHAG RNA, CHAG DNA, CHAG binding activity, and the presence of translocations or point
10 mutations can be determined as described above.

Kits for diagnostic use are also provided, that comprise in one or more containers an anti-CHAG antibody, and, optionally, a labeled binding partner to the antibody. Alternatively, the anti-CHAG antibody can be labeled (with a detectable marker, *e.g.*, a chemiluminescent, enzymatic, fluorescent, or radioactive moiety). A kit is also provided that comprises in one or
15 more containers a nucleic acid probe capable of hybridizing to *CHAG* RNA. In a specific embodiment, a kit can comprise in one or more containers a pair of primers (*e.g.*, each in the size range of 6-30 nucleotides) that are capable of priming amplification [*e.g.*, by polymerase chain reaction (see *e.g.*, Innis *et al.*, 1990, PCR Protocols, Academic Press, Inc., San Diego, CA), ligase chain reaction (see EP 320,308) use of Q β replicase, cyclic probe reaction, or other
20 methods known in the art] under appropriate reaction conditions of at least a portion of a *CHAG* nucleic acid. A kit can optionally further comprise in a container a predetermined amount of a purified CHAG protein or nucleic acid, *e.g.*, for use as a standard or control.

(8) Screening for CHAG Modulators

25 CHAG nucleic acids, proteins, and derivatives also have uses in screening assays to detect molecules that specifically bind to CHAG nucleic acids, proteins, or derivatives and thus have potential use as agonists or antagonists of CHAG. In particular, molecules that thus affect cardiac hypertrophy. In a preferred embodiment, such assays are performed to screen for molecules with potential utility as anti-cardiac-hypertrophy agents for drug development. The
30 invention thus provides assays to detect molecules that specifically bind to CHAG nucleic acids, proteins, or derivatives. For example, recombinant cells expressing *CHAG* nucleic acids can be used to recombinantly produce CHAG proteins in these assays, to screen for molecules that bind to a CHAG protein. Molecules (*e.g.*, putative binding partners of CHAG) are contacted with the

CHAG protein (or fragment thereof) under conditions conducive to binding, and then molecules that specifically bind to the CHAG protein are identified. Similar methods can be used to screen for molecules that bind to CHAG derivatives or nucleic acids. Methods that can be used to carry out the foregoing are commonly known in the art.

- 5 By way of example, diversity libraries, such as random or combinatorial peptide or non-peptide libraries can be screened for molecules that specifically bind to CHAG. Many libraries are known in the art that can be used, *e.g.*, chemically synthesized libraries, recombinant (*e.g.*, phage display libraries), and *in vitro* translation-based libraries.

Examples of chemically synthesized libraries are described in Fodor *et al.*, *Science*
10 251:767-773 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991); Lam *et al.*, *Nature* 354:82-84 (1991); Medynski, *Bio/Technology* 12:709-710 (1994); Gallop *et al.*, *J. Medicinal Chemistry* 37(9):1233-1251 (1994); Ohlmeyer *et al.*, *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993); Erb *et al.*, *Proc. Natl. Acad. Sci. USA* 91:11422-11426 (1994); Houghten *et al.*, *Biotechniques* 13:412 (1992); Jayawickreme *et al.*, *Proc. Natl. Acad. Sci. USA* 91:1614-1618 (1994); Salmon *et al.*,
15 *Proc. Natl. Acad. Sci. USA* 90:11708-11712 (1993); PCT Publication No. WO 93/20242; and Brenner and Lerner, *Proc. Natl. Acad. Sci. USA* 89:5381-5383 (1992).

Examples of phage display libraries are described in Scott and Smith, *Science* 249:386-390 (1990); Devlin *et al.*, *Science* 249:404-406 (1990); Christian, R.B., *et al.*, *J. Mol. Biol.* 227:711-718 (1992); Lenstra, *J. Immunol. Meth.* 152:149-157 (1992); Kay *et al.*, *Gene* 128:59-65
20 (1993); and PCT Publication No. WO 94/18318 dated August 18, 1994.

In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated April 18, 1991; and Mattheakis *et al.*, *Proc. Natl. Acad. Sci. USA* 91:9022-9026 (1994).

By way of examples of non-peptide libraries, a benzodiazepine library (*see e.g.*, Bunin *et al.*, *Proc. Natl. Acad. Sci. USA* 91:4708-4712 (1994)) can be adapted for use. Peptide libraries
25 (Simon *et al.*, *Proc. Natl. Acad. Sci. USA* 89:9367-9371 (1992)) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh *et al.*, *Proc. Natl. Acad. Sci. USA* 91:11138-11142 (1994).

30 Screening the libraries can be accomplished by any of a variety of commonly known methods. See, *e.g.*, the following references, which disclose screening of peptide libraries: Parmley and Smith, *Adv. Exp. Med. Biol.* 251:215-218 (1989); Scott and Smith, *Science* 249:386-390 (1990); Fowlkes *et al.*, *BioTechniques* 13:422-427 (1992); Oldenburg *et al.*, *Proc.*

Natl. Acad. Sci. USA 89:5393-5397 (1992); Yu *et al.*, *Cell* 76:933-945 (1994); Staudt *et al.*, *Science* 241:577-580 (1988); Bock *et al.*, *Nature* 355:564-566 (1992); Tuerk *et al.*, *Proc. Natl. Acad. Sci. USA* 89:6988-6992 (1992); Ellington *et al.*, *Nature* 355:850-852 (1992); U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner *et al.*;
5 Rebar and Pabo, *Science* 263:671-673 (1993); and PCT Publication No. WO 94/18318.

In a specific embodiment, screening can be carried out by contacting the library members with a CHAG protein (or nucleic acid or derivative) immobilized on a solid phase and harvesting those library members that bind to the protein (or nucleic acid or derivative). Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley
10 and Smith, *Gene* 73:305-318 (1988); Fowlkes *et al.*, *BioTechniques* 13:422-427 (1992); PCT Publication No. WO 94/18318; and in references cited hereinabove.

In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, *Nature* 340:245-246 (1989); Chien *et al.*, *Proc. Natl. Acad. Sci. USA* 88:9578-9582 (1991)) can be used to identify molecules that specifically bind to a CHAG protein
15 or derivative.

(9) Assays for CHAG and Derivatives and Analogs Thereof

The functional activity of CHAG proteins, and derivatives, fragments and analogs thereof
20 can be assayed by various methods. Potential modulators (*e.g.*, inhibitors, agonists and antagonists) of CHAG activity, *e.g.*, anti-CHAG antibodies and CHAG antisense nucleic acids can be assayed for the ability to modulate expression and/or activity of CHAG.

For example, in one embodiment, where one is assaying for the ability to bind or compete with wild-type CHAG for binding to an anti-CHAG antibodies, various immunoassays known in
25 the art can be used, including but not limited to competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (*e.g.*, gel
30 agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary

antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

The expression of the *CHAG* genes (both endogenous genes and those expressed from
5 cloned DNA containing these genes) can be detected using techniques known in the art,
including but not limited to Southern hybridization (Southern, *J. Mol. Biol.* 98: 503-517 (1975)),
northern hybridization (e.g. Freeman *et al.*, *Proc. Natl. Acad. Sci. USA* 80: 4094-4098 (1983),
restriction endonuclease mapping (Sambrook *et al.*, 1982, *Molecular Cloning. A Laboratory*
Manual, Cold Spring Harbor Press, New York), and DNA sequence analysis. Polymerase chain
10 reaction amplification (PCR; U.S. Patent Nos. 4,683,202, 4,683,195, and 4,889,818; Gyllenstein
et al., *Proc. Natl. Acad. Sci. USA* 85: 7652-7657 (1988); Ochman *et al.*, *Genetics* 120: 621-623
(1988); Loh *et al.*, *Science* 243: 217-220 (1989)) followed by Southern hybridization or RNase
protection (*Current Protocols in Molecular Biology*, John Wiley and Sons, New York, 1997)
with probes specific for *CHAG* genes in various cell types. Methods of amplification other than
15 PCR commonly known in the art can be employed. In one embodiment, Southern hybridization
can be used to detect genetic linkage of *CHAG* gene mutations to physiological or pathological
states. Various cell types, at various stages of development, can be characterized for their
expression of *CHAG* expression. The stringency of the hybridization conditions for northern or
Southern blot analysis can be manipulated to ensure detection of nucleic acids with the desired
20 degree of relatedness to the specific probes used. Modifications to these methods and other
methods commonly known in the art can be used.

In one embodiment, a Therapeutic of the invention can be assayed for activity in treating
or preventing cardiac hypertrophy by contacting cultured cells that exhibit an indicator of a
cardiac hypertrophy disease *in vitro* with the Therapeutic; and comparing the level of said
25 indicator in the cells contacted with the Therapeutic, with said level of said indicator in cells not
so contacted, wherein an altered level of such indicators in said contacted cells indicates that the
Therapeutic has activity in treating or preventing cardiac hypertrophy disease. *In vitro* models
for cardiac hypertrophy include, but are not limited to: cultured myocytes isolated from neonate
and adult hearts, isolated papillary muscles, skinned fibers, and beating or arrested isolated
30 perfused hearts subjected to various pressure and volume-loading conditions (Cooper *et al.*, *J.*
Mol. Cell. Cardiol. 21(Suppl 5):11-301 (1989); Simpson *et al.*, *J. Mol. Cell. Cardiol.* 21(Suppl
5):79-89 (1989); Morgan and Baker, *Circulation* 83:13-251991; Chien *et al.*, *FASEB. J.* 5:3037-
3046 (1991); Schneider and Parker, *Mol. Biol. Med.* 8:167-183 (1991)). Specific examples of

such cardiac hypertrophy indicators include, but are not limited to: increased myocardial cell size (Simpson *et al.*, *J. Clin. Invest.* 72:732-738 (1983)), an increase in the assemble of an individual contractile protein (MLC-2) into organized contractile units (Iwaki *et al.*, *J. Biol. Chem.* 265:13809-13817 (1990)), accumulation of contractile proteins (Lee *et al.*, *J. Biol. Chem.* 263:7352-7358 (1988)), increased protein content per cell (Lai *et al.*, *Am. J. Physiol.* 271:H2197-H2208 (1996)), activation of the β -MHC gene and repression of the α -MHC gene (Lompré *et al.*, *Int. Rev. Cytol.* 124:137-186 (1991)), transient up-regulation of α -skeletal isoactin gene (Izumo *et al.*, *Proc. Natl. Acad. Sci. USA* 85:339-343 (1988)); permanent reactivation of α -smooth actin isoform (Black *et al.*, *J. Clin. Invest.* 88:1581-1588 (1991)), increased expression of myosin light chains 1 and 2 (Cummins, *Biochem. J.* 205:195-204 (1982)), transient activation of β isoform of tropomyosin (Izumo *et al.*, *Proc. Natl. Acad. Sci. USA* 85:339-343 (1988)), increased expression of fetal type isoenzymes (BB+MB) of creatine kinase and of the M-LDH isoform of lactate dehydrogenase (Ingwall *et al.*, *N. Engl. J. Med.* 313:1050-1054 (1985)), accumulation of the fetal forms of cellular fibronectin in the wall of coronary arteries and in focal areas of the myocardium early after rat aortic stenosis (Samuel *et al.*, *J. Clin. Invest.* 88:1737-1746 (1991)), transient upregulation of *c-fos*, *c-myc*, *c-jun*, *junB*, and *nur77* (Komuro *et al.*, *Circ. Res.* 62:1075-1079 (1988); Izumo *et al.*, *Proc. Natl. Acad. Sci. USA* 85:339-343 (1988); Rockman *et al.*, *Proc. Natl. Acad. Sci. USA* 88:8277-8281 (1991)), a transient and early expression of three heat-shock proteins (HSP70, HSP68, and HSP58) (Delcayre *et al.*, *J. Clin. Invest.* 82:460-468 (1988)), accumulation of mRNAs encoding transforming growth factor β 1 (TGF β 1), insulin like growth factor-I, and early growth response factor 1 (Egr-1), a serum-inducible zinc finger protein (Schneider and Parker, *Mol. Biol. Med.* 8:167-183 (1991); Chien *et al.*, *FASEB. J.* 5:3037-3046 (1991)), the ventricular expression of atrial natriuretic factor (ANF) (Mercadier and Michael, In Swynghedauw B, ed. *Research in Cardiac Hypertrophy and Failure*. Paris, INSERM/ John Libbey Eurotext, pp 401-413 (1990)), and the decreased expression of the slow skeletal/cardiac form SERCA2a isoform of the Ca²⁺ATPase of the sarcoplasmic reticulum (Komuro *et al.*, *J. Clin. Invest.* 83:1102-1108 (1989); Nagai *et al.*, *Proc. Natl. Acad. Sci. USA* 86:2966-2970 (1989); De la Bastie *et al.*, *Circ. Res.* 66:554-564 (1990); Mercadier *et al.*, *J. Clin. Invest.* 85:305-309 (1990)).

30 In another embodiment, a Therapeutic of the invention can be assayed for activity in treating or preventing cardiac hypertrophy by administering the Therapeutic to a test animal that exhibits one or more symptoms of a cardiac hypertrophy disease, or that is predisposed to develop symptoms of a cardiac hypertrophy disease; and measuring the change in said symptoms

of the cardiac hypertrophy disease after administration of said Therapeutic, wherein a reduction in the severity of the symptoms of the cardiac hypertrophy or prevention of the symptoms of the cardiac hypertrophy disease indicates that the Therapeutic has activity in treating or preventing cardiac hypertrophy disease. Such a test animal can be any one of a number of animal models known in the art for cardiac hypertrophy disease. Cardiac hypertrophy can be induced by either mechanical triggers via stretch, load, cell deformation, and contraction, and by trophic triggers such as peptide derived growth factors (including, fibroblast growth factors, transforming growth factors, angiotensin II, and endothelin), thyroxine, adrenocorticoids, insulin, growth hormone, or adrenoreceptor activation (Boheler and Schwartz, *TCM* 2(5):176-182 (1992)). Animal models include but are not limited to: cardiac hypertrophy induced by chronic or acute administration of adrenergic agonists or antagonists, thyroxine, angiotensin II, converting enzyme inhibitors (Boheler and Schwartz, *TCM* 2(5):176-182 (1992)), and endothelin-1 (Shubeita *et al.*, *J. Biol. Chem.* 265(33):20555-20562 (1990)), and by surgical procedures that produce constriction of aorta, aortic incompetence, and aortocaval fistula (Mercadier *et al.*, *Circ. Res.* 49:525-532 (1991)), and in the spontaneous hypertensive rat (SHR) (Boluyt *et al.*, *Circ. Res.* 75:23-32 (1994)). Symptoms of the cardiac hypertrophy in the animal models include but are not limited to: an increase in the absolute heart weight and heart weight-to-body weight ratio, and absolute ventricular weight and ventricular-weight-to-body weight ratio (Lai, *et al.*, *Am. J. Physiol.* 271:H2197-H2208 (1996)), and any of the cardiac hypertrophy indicators discussed in the preceding paragraph.

(10) Pharmaceutical Compositions

The invention provides methods of treatment and prophylaxis by administering to a subject of an effective amount of a Therapeutic of the invention. In a preferred aspect, the Therapeutic is substantially purified. The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human. In a specific embodiment, a non-human mammal is the subject.

Formulations and methods of administration that can be employed when the Therapeutic comprises a nucleic acid are described *supra*; additional appropriate formulations and routes of administration can be selected from among those described hereinbelow.

Various delivery systems are known and can be used to administer a Therapeutic of the invention, *e.g.*, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the Therapeutic, receptor-mediated endocytosis (see, *e.g.*, Wu and Wu, *J.*

Biol. Chem. 262:4429-4432 (1987)). construction of a Therapeutic nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

In another embodiment, the Therapeutic can be delivered in a vesicle, in particular a liposome (*see* Langer, *Science* 249:1527-1533 (1990); Treat *et al.*, in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see generally ibid.*)

In yet another embodiment, the Therapeutic can be delivered in a controlled release system. In one embodiment, a pump may be used (*see* Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald *et al.*, *Surgery* 88:507 (1980); Saudek *et al.*, *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (*see* *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); *see also* Levy *et al.*, *Science* 228:190 (1985); During *et al.*, *Ann. Neurol.* 25:351 (1989); Howard *et al.*, *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, *i.e.*, the brain, thus requiring only a fraction of the systemic dose (*see, e.g.*, Goodson, in *Medical Applications of*

Controlled Release, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the Therapeutic is a nucleic acid encoding a protein
5 Therapeutic, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.*, by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, DuPont), or coating with lipids or cell-surface receptors or transfecting agents, or by
10 administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see *e.g.*, Joliot *et al.*, *Proc. Natl. Acad. Sci. USA* 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid Therapeutic can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions
15 comprise a therapeutically effective amount of a Therapeutic, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is
20 administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable
25 pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules,
30 powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable

pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the Therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.

5 In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the
10 ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachet indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an
15 ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The Therapeutics of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with
20 free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the Therapeutic of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be
25 employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges
30 for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight;

oral formulations preferably contain 10% to 95% active ingredient.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

(11) Animal Models

The invention also provides animal models. In one embodiment, animal models for diseases and disorders involving cardiac hypertrophy are provided. Such an animal can be initially produced by promoting homologous recombination between a *CH* gene in its chromosome and an exogenous *CH* gene that has been rendered biologically inactive (preferably by insertion of a heterologous sequence, *e.g.*, an antibiotic resistance gene). In a preferred aspect, this homologous recombination is carried out by transforming embryo-derived stem (ES) cells with a vector containing the insertionally-inactivated *CH* gene, such that homologous recombination occurs, followed by injecting the ES cells into a blastocyst, and implanting the blastocyst into a foster mother, followed by the birth of the chimeric animal ("knockout animal") in which a *CH* gene has been inactivated (see Capecchi, *Science* 244:1288-1292 (1989)). The chimeric animal can be bred to produce additional knockout animals. Such animals can be mice, hamsters, sheep, pigs, cattle, etc., and are preferably non-human mammals. In a specific embodiment, a knockout mouse is produced.

Such knockout animals are expected to develop or be predisposed to developing diseases or disorders involving cardiac hypertrophy and thus can have use as animal models of such diseases and disorders, *e.g.*, to screen for or test molecules for the ability to treat or prevent such diseases or disorders.

In a separate embodiment, animal models for diseases and disorders involving cardiac hypertrophy are provided. Such an animal can be initially produced by promoting homologous recombination between a *CH* gene in its chromosome and an exogenous *CH* gene that would be over-expressed or mis-expressed (preferably by expression under a strong promoter). In a preferred aspect, this homologous recombination is carried out by transforming embryo-derived stem (ES) cells with a vector containing the over-expressed or mis-expressed *CH* gene, such that homologous recombination occurs, followed by injecting the ES cells into a blastocyst, and

implanting the blastocyst into a foster mother, followed by the birth of the chimeric animal in which a *CH* gene has been over-expressed or mis-expressed (see Capecchi, *Science* 244:1288-1292 (1989)). The chimeric animal can be bred to produce additional knockout animals. Such animals can be mice, hamsters, sheep, pigs, cattle, etc., and are preferably non-human mammals. In a specific embodiment, a knockout mouse is produced.

Such animals are expected to develop or be predisposed to developing diseases or disorders involving cardiac hypertrophy and thus can have use as animal models of such diseases and disorders, *e.g.*, to screen for or test molecules for the ability to inhibit function of *CH* genes and proteins and thus treat or prevent such diseases or disorders.

(12) Specific Examples

To obtain a more detailed understanding of the changes in gene expression occurring during pressure overload hypertrophy, QEA was used to identify expression differences in a rat surgical model of pressure overload (POL) induced cardiac hypertrophy. This *in vivo* model is attractive for expression analysis as there are limited changes in tissue cellularity by infiltration of non-resident cells. The tissue reaction to acute POL is primarily due to an intrinsic response of the myocardium including hypertrophy of the cardiomyocytes, in addition to hyperplasia of endothelial, smooth muscle, and mesenchymal cells (Weber and Brilla, *Circulation* 83:1849-1865 (1991); Cooper, IV, *Ann. Rev. Physiol.* 49:501-518 (1987)). While this process is initially adaptive, there is ultimately a deterioration of contractile function accompanied by interstitial and perivascular fibrosis and increased wall stiffness (Kimura *et al.*, *Heart Circ. Physiol.* 25:H1006-H1011 (1989); Batra and Rakusan, *J. Cardiovasc. Pharmacol.* 17 (Suppl 2):S151-S153 (1991)). Abdominal aortic constriction leads to moderate hemodynamic overload (Boheler and Schwartz, *TCM* 2:176-182 (1992); Grossman *et al.*, *J. Clin. Invest.* 56:56-64 (1975)), with the heart responding by concentric hypertrophy of the left ventricle, a process that leads to normalization of systolic wall stress (Morgan and Baker, *Circulation* 83:13-25 (1991)). Although increased load is thought to be the primary stimulus for this response, focal necrosis in the myocardium may also contribute to increased wall stress in this model.

(a) Materials and Methods

Total cellular RNA was extracted from 5 mg of heart tissue by first grinding the tissue into a fine powder on liquid nitrogen. The tissue powder was transferred to a tube containing 500 μ l Triazol reagent (see Chomczynski *et al.*, 1987, *Anal. Biochem.* 162 156-159 and

Chomczynski *et al.*, 1993, *Biotechniques* 15:532-532.536-537; reagent obtained from Life Technologies, Gaithersburg, MD) and was dispersed in the Triazol using a Polytron homogenizer from Brinkman Instruments (Westbury, NY). The cellular RNA fraction was extracted with 50 μ l BCP (1-bromo-3-chloropropane) (Molecular Research, Cincinnati, OH). The extraction mixture was centrifuged for 15 minutes at 4°C at 12,000xG, and the aqueous phase was removed to a fresh tube. The RNA was then precipitated with 0.5 volumes isopropanol per original amount of Triazol reagent used, and the sample centrifuged at room temperature for 10 minutes at 12,000xG. The supernatant was discarded, the pellet washed with 70% ethanol and then centrifuged at room temperature for 5 minutes at 12,000xG. Finally the 70% ethanol was removed and the centrifuge tube was let stand to dry in an inverted position. The resulting RNA pellet was resuspended in 100 μ l water (1 μ l per mg of original tissue weight) and heated to 55°C until completely dissolved.

The RNA samples were then treated with DNase to remove DNA. 28 μ l of 5X reverse transcriptase buffer (Life Technologies, Gaithersburg, MD), 10 μ l 0.1 M DTT, and 5 units RNAGuard per 100 mg starting tissue (Pharmacia Biotech, Uppsala, Sweden) and 1 unit RNase-free DNase I (Pharmacia Biotech) per 100 mg starting tissue were added to the resuspended RNA samples. The reaction mixture was incubated at 37°C for 20 minutes. The total RNA concentration was quantified by measuring OD₂₆₀ of a 100-fold dilution and the samples stored at -20°C.

Poly-adenylated mRNA was isolated from the total RNA preparations using magnetic bead mediated oligo-dT detection with the Dynabeads mRNA Direct Kit from Dynal (Oslo, Norway) as directed by the manufacturer. The poly-adenylated RNA was harvested in a small volume of water, quantified by OD₂₆₀ measurement, and stored at -20°C.

cDNA was synthesized from the poly-adenylated RNA as follows. The poly A⁺ RNA was mixed with 50 ng random hexamers (50 ng/ μ l) in 10 μ l of water. The mixture was heated to 70°C for 10 minutes, quick chilled in ice-water slurry, and kept on ice for 1-2 minutes. The condensate was collected by centrifugation in a microfuge for 10 seconds.

The first-strand synthesis was carried out by adding a reaction mixture of 4 μ l 5x first strand buffer (from the BRL kit), 2 μ l 100 mM DTT, 1 μ l 10 mM dNTP mix, and 2 μ l water to the primer-annealed RNA. The reaction mixtures were incubated at 37°C for 2 minutes, 1 μ l of Superscript II (BRL) (following manufacturer's recommendations) was added, and the reactions were then incubated at 37°C for 1 hour.

To synthesize the second cDNA strand, the samples were placed on ice, 30 μ l of 5X

Second strand buffer, 90 µl of cold water, 3 µl of 10 mM dNTP, 1 µL (10 units) of *E. coli* DNA ligase (BRL), 4 µl (40 units) of *E. coli* DNA polymerase (BRL), and 1 µl (3.5 units) of *E. coli* RNase H (BRL) were added to the tubes, and the reactions were incubated for 2 hours at 16°C. The resulting cDNA was then incubated with 2 µl of T4 DNA polymerase (5 units) at 16°C for 5 minutes.

The resulting cDNA was dephosphorylated with Arctic Shrimp Alkaline Phosphatase ("SAP"; obtained from USB); 20 µl 10X SAP buffer, 25 µl of water, and 5 µl (5 units) of SAP were added to the reaction mixtures and incubated at 37°C for 30 minutes.

The cDNA was extracted with phenol-chloroform, chloroform-isoamyl alcohol, precipitated from the aqueous phase by addition of NaOAc to 0.3 M, 20 µg glycogen, and 2 volumes of ethanol, incubation at -20°C for 10 minutes, and collected by centrifugation at 14,000xg for 10 minutes. The supernatant was removed and the pellet washed with 75% ethanol, resuspended in TE, and the cDNA quantitated.

For subsequent QEA processing, 75 ng cDNA was transferred to a separate tube, resuspended in TE to a concentration 600 ng/ml, and stored at -20°C.

QEA analysis was performed as disclosed in PCT Publication WO 97/15690 dated May 1, 1997. Restriction enzyme pairs for the identified genes are listed in Tables I and II. Adapter molecules for the QEA analysis were prepared from linker and primer oligonucleotides. One set of primers were labeled with FAM fluorescent label and one set were labeled with a biotin moiety. The adapters were prepared by mixing the linker and primer oligonucleotides together in water at a concentration ratio of 1:20 (linker to primer) with the primer at a total concentration of 50 pm/µl. The mixture was incubated at 50°C for 10 minutes and then allowed to cool slowly to room temperature to anneal the linkers and primers. The adapters were stored at -20°C.

The QEA reactions were performed using an automated QEA procedure. Reactions were preformed in a standard 96 well thermal cycler format using a Beckman Biomek 2000 robot (Beckman, Sunnyvale, CA). The 3 cDNA samples were analyzed in triplicate with corresponding restriction enzyme pairs. All steps were performed by the robot, including solution mixing, from user provided stock reagents, and temperature profile control.

The RE/ligase reaction contained the following components per reaction:

1. 1 U each restriction enzyme (New England Biolabs, Beverly, MA)
2. 1 µl of each annealed adapter prepared as above (10 pm)
3. 0.1 µl T4 DNA ligase [1 U/µl] (Life Technologies (Gaithersburg, MD)
4. 1 µl ATP (Life Technologies, Gaithersburg, MD)
5. 5 ng of the prepared cDNA

6. 1.5 μ l 10X NEB 2 buffer from New England Biolabs (Beverly, MA)
7. 0.5 μ l of 50 mM $MgCl_2$
8. Water to bring total volume to 10 μ l and transfer to thermal cycler.

5 The robot performed the RE/ligation reaction in a PTC-100 Thermal Cycler equipped with a mechanized lid from MJ Research (Watertown, MA) with the following temperature profile: 15 minutes at 37°C, ramp down 21°C in 5 minutes, 16°C for 30 minutes, 37°C for 10 minutes, and 65°C for 10 minutes.

The PCR reaction mix contained the following components per reaction:

- 10 1. 10 μ l 5X E-Mg (300 mM Tris-HCl pH 9.0, 75 mM $(NH_4)_2SO_4$)
2. 100 pm of primers (one set labeled with FAM; the other set labeled with biotin).
3. 1 μ l 10 mM dNTP mix (Life Technologies, Gaithersburg, MD)
4. 2.5 U of 50:1 Taq polymerase (Life Technologies, Gaithersburg, MD) :
Pfu polymerase (Stratagene, La Jolla, CA)
- 15 5. Water to bring volume to 35 μ l per PCR reaction

The PCR mix was heated to 72°C and 35 μ l was transferred to each digestion/ligation reaction. The PTC-100 Thermal Cycler then performed the PCR reaction with a thermal profile of 72°C for 10 minutes, 15 cycles of 95°C for 30 seconds and 68°C for 1 minute, and then 72°C
20 for 10 minutes, and finally holding the reactions at 4°C.

Before further analysis, the QEA products were subjected to a post-PCR clean up protocol as follows:

1. Streptavidin magnetic beads (Catalog No. MSTR0510 of CPG, Lincoln Park, N.J.) were prepared (3 μ l of beads for every 5 μ l of QEA reaction product) by pre-washing beads in 10
25 μ l binding buffer (5 M NaCl, 10 mM Tris, pH 8.0, 1 mM EDTA) per 5 μ l original volume of QEA reaction product.
2. 10 μ l of washed beads were dispensed in a 96 well FALCONJ TC plate for every QEA sample processed.
3. QEA products were added to the beads, mixed well and incubated for 30 minutes at 50°C.
- 30 4. The sample volume was made 100 μ l with binding buffer, the plate placed on a 96 well magnetic particle concentrator, and the beads allowed to migrate for 5 minutes.
5. The liquid was then removed, and 200 μ l washing buffer (10 mM Tris, pH 7.4, 10 mM EDTA) added per well.
- 35 6. Washing step 5 was repeated.

For analysis, the beads were resuspended in 5 μ l loading buffer (80% deionized

formamide, 20% 25 mM EDTA, pH 8.0, 50 mg/ml Blue dextran) per 5 µl of beads, and the supernatant was then analyzed by electrophoresis on an ABI 377 (Applied Biosystems, Inc.) automated sequencer under denaturing conditions using the Gene Scan software (ABI) for analysis. The GeneScan 500 ROX ladder was diluted 1:10 in loading buffer and analyzed as a size control.

Oligonucleotide poisoning was performed to confirm the identity of the differentially expressed fragments. Essentially, an unlabeled oligonucleotide having a nucleotide sequence able to hybridize to the identified sequence (and prevent amplification with the labeled primers) was included in a PCR reaction using the QEA reaction products as substrate.

Specifically, for the oligonucleotide poisoning, each reaction mixture contained 1 µl of a 1:100 dilution of the QEA reaction products, 5 µl TB 2.0 (500 mM Tris-HCl pH 9.15, 160 mM (NH₄)₂SO₄, 20 mM MgCl₂), 2 µl 10 mM equimolar mixture of all four dNTPs, 0.2 µl each primers (100 pm/ml), 2 µl CHAG poisoning primer (1000 pm/ml), 1 µl 5 M betaine, 1 µl NEB 2 buffer (10 mM Tris-HCl, 10 mM MgCl₂, 50 mM NaCl, 1 mM DTT (pH 7.9 at 25°C), 0.25 µl 25 U/ml of a 16:1 mixture of KlenTaq:pfu, and 38 µl water.

The following PCR temperature protocol was performed in a thermal cycler for 13 cycles:

96°C for 30 seconds;

57°C for 1 minute;

72°C for 2 minutes.

The amplified products were held at 4°C. and then analyzed as described above on the automatic sequencer.

(b) Experimental Results

At two weeks post surgery there was a significant increase in the ventricle weight:body weight ratio (4.19:0.52 mg/g) compared to the sham surgery group (2.59:0.52 mg/g), with up to a 60% increase in ventricle mass.

5 QEA was performed on pressure overloaded hearts, sham surgery hearts, and non-operated hearts and comparisons of expression profiles were made *in silico* between the pressure overload and sham surgery hearts and the pressure overload and non-operated hearts. The first comparison controls for differences induced by surgery, the second allows for the detection of all surgery-related changes in gene expression. Bands representing genes differentially expressed in
10 both comparisons were confirmed for gene identity by oligonucleotide poisoning of the identified differentially expressed fragments with matches in the database and direct cloning and sequencing of bands with no matches from the publicly available database.

A total of 12,000 gene fragments per sample group were examined for expression levels, which represents approximately 6,000 unique expressed sequences in the heart. The comparison
15 between the pressure overload hearts and the sham surgery hearts yielded 74 differences (0.6%) while the pressure overload versus non-operated hearts gave 117 differences (1.0%). When these two analyses are combined, the number of gene fragments differentially expressed between the pressure overload hearts and both the sham surgery and normal hearts is only 39 fragments (0.3%). Oligonucleotide poisoning, cloning and sequence analysis of the differentially expressed
20 bands revealed 32 differentially expressed genes (See Tables I and II).

Genes identified by QEA (Tables I & II) include those known to be regulated in cardiac hypertrophy (*ANF*, *ANF precursor*, *ANP*, α *skeletal actin*, *MLC2*, α *and* β *MHC*, and *fibronectin*) and genes not previously implicated in hypertrophy (*CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, *CH-9*, and α -*Enolase*, *Atrial Natriuretic Peptide (ANP)*, *Antizyme Inhibitor*,
25 *Biglycan*, *Cytochrome Oxidase I*, *Cytochrome Oxidase II*, *Cyclin G*, *D-binding protein*, *Desmin*, *Fibrillin*, *Laminin α -1*, *p85*, *Preproenkephalin*, *Protein Kinase C-Binding Protein β 15* and genes encoding 5.8S, 18S and 28S rRNAs). The identification of genes previously associated with cardiac hypertrophy provides biological validation of QEA. Prominent among the known genes are myocyte-specific transcripts that represent re-expression of a fetal molecular phenotype.
30 These include ANP, α -skeletal actin, and myosin heavy chain isoform switching (Samuel, *et al.*, *J. Clin. Invest.* **88**:1737-1746 (1991)). Induction of the fetal isoform of fibronectin in cardiac non-myocytes and smooth muscle has also been described (Chapman *et al.*, *Circ. Res.* **67**:787-794 (1990)), and is consistent with the fibronectin induction detected by QEA (Table I, Fig. 2).

Increased collagen III and IV mRNA represents changes in both fibrillar and basement membrane components during pressure overload (SchÖnherr, *et al.*, *J. Biol. Chem.* 270:2776-2783 (1995); Heimer *et al.*, *J. Mol. Cell. Cardiol.* 27:2191-2198 (1995)).

5 Detectable changes in steady state expression by QEA ranged from -1.5 for weak repression of *CH-1* to 20-fold induction of *CH-9*. To provide independent confirmation and quantitative validation of QEA, Northern blotting was used to measure changes in steady state mRNA levels. Induction values for ANP, p85, biglycan, laminin, desmin, and α -skeletal actin were plotted against QEA results (Fig. 1) to illustrate that Northern analysis confirmed the QEA results. Desmin, p85 and laminin showed the largest difference between Northern and QEA values, either due to errors inherent in generating reproducible and normalized quantitative Northern data, or stochastic errors due to the sample size used for the two techniques. Nevertheless, p85 and laminin did show induction by Northern analysis, as did the remaining genes, with a 50% to 3-fold difference in the value obtained. This comparison suggests that QEA does not introduce a systematic bias in either over- or underestimating changes in mRNA levels.

15 Numerous genes have been described in association with the molecular phenotype of cardiac hypertrophy. However, QEA of POL ventricles identified a relatively small number of differences. Part of this discrepancy may be due to model-specific sensitivity in detecting expression. To determine if QEA potentially missed genes due to an incomplete set of subsequences, expression below the limit of sensitivity, or simply did not score differential expression, a directed search of the QEA database was performed for five genes. Numerous fragments corresponding to TGF- β 1, collagen-I, angiotensin converting enzyme, angiotensinogen, and endothelin-1 were identified based on length and end restriction sites. None of the fragments identified in the directed query were identified by QEA as differentially expressed either by software or by visual inspection. This analysis is consistent with the small number of differences found by QEA and suggests that a representative population of cDNA fragments is being sampled for expression differences.

25 The changes in gene expression found by QEA represent re-expression of a fetal phenotype in myocytes and non-myocytes, extracellular matrix expression, and cell cycle-related genes. A variety of cell types are involved in the tissue response to POL, some of which may be minor constituents of the myocardium. It is therefore likely that there are significant changes in expression occurring below the current sensitivity of QEA. For instance, if, in a cell type representing 10% of the total population sampled, a gene undergoes a 10-fold change which is at

a constant and equivalent level in the other 90% the cells. the total change observed by QEA would be less than twofold. If the expression levels of that gene are even higher in the non-modulating cells then the overall difference is further diminished, making the study of more complex tissues by expression analysis difficult without sophisticated cell type-specific
5 dissection or purification. Therefore, it is very likely that some of the modest differences found by QEA in the total heart will be due to large differences in a subset of cells within the myocardium.

10 The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

 Various publication are cited herein, the disclosures of which are incorporated by
15 reference in their entireties.

WHAT IS CLAIMED IS:

1. A purified protein selected from the group consisting of a CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9 protein.
2. The protein of claim 1 which is a human protein.
3. A purified protein encoded by a nucleic acid hybridizable to a DNA having a sequence consisting of the coding region of the nucleic acids selected from the group consisting of SEQ. ID NO:1, SEQ. ID NO:2, SEQ. ID NO:3, SEQ. ID NO:4, SEQ. ID NO:5, SEQ. ID NO:6, SEQ. ID NO:7, SEQ. ID NO:8, and SEQ. ID NO:9.
4. A purified derivative or analog of the protein of claim 1, which is able to be bound by an antibody directed against a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9.
5. A protein comprising an amino acid sequence that has at least 60% identity to a domain of a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9, in which the percentage identity is determined over an amino acid sequence of identical size to the domain.
6. A protein comprising an amino acid sequence that has at least 90% identity to a domain of a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9, in which the percentage identity is determined over an amino acid sequence of identical size to the domain.
7. A chimeric protein comprising a fragment of a first protein, selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9, consisting of at least 6 amino acids fused via a covalent bond to an amino acid sequence of a second protein, in which the second protein is not the first protein.
8. The chimeric protein of claim 7 in which the fragment of the first protein is a fragment capable of being bound by an antibody against the first protein.

9. An antibody which immunospecifically binds a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9, or a fragment or derivative of said antibody containing the binding domain thereof.
10. The antibody of claim 9 which is monoclonal.
11. An isolated nucleic acid comprising a nucleotide sequence encoding a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9.
12. The nucleic acid of claim 11 which is a DNA.
13. An isolated nucleic acid comprising a nucleotide sequence complementary to the nucleotide sequence of claim 11.
14. The nucleic acid of claim 11 in which the protein is a human protein.
15. An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ. ID NO:1, SEQ. ID NO:2, SEQ. ID NO:3, SEQ. ID NO:4, SEQ. ID NO:5, SEQ. ID NO:6, SEQ. ID NO:7, SEQ. ID NO:8 and SEQ. ID NO:9.
16. An isolated nucleic acid hybridizable to the inverse complement of a DNA selected from the group consisting of SEQ. ID NO:1, SEQ. ID NO:2, SEQ. ID NO:3, SEQ. ID NO:4, SEQ. ID NO:5, SEQ. ID NO:6, SEQ. ID NO:7, SEQ. ID NO:8 and SEQ. ID NO:9.
17. An isolated nucleic acid comprising a fragment of the nucleic acid of claim 11, consisting of at least 8 nucleotides.
18. An isolated nucleic acid comprising a nucleotide sequence encoding a fragment of the protein of claim 4.

19. An isolated nucleic acid comprising a nucleotide sequence encoding the chimeric protein of claim 7.
20. An isolated nucleic acid comprising a nucleotide sequence encoding the protein of claim 5.
21. A recombinant cell containing the nucleic acid of claim 11, which nucleic acid is recombinant.
22. A recombinant cell containing the nucleic acid of claim 14, which nucleic acid is recombinant.
23. A recombinant cell containing the nucleic acid of claim 15 or 16, which nucleic acid is recombinant.
24. A method of producing a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9 comprising growing a cell containing the nucleic acid of claim 11, which nucleic acid is recombinant, such that the encoded said protein is expressed by the cell, and recovering the expressed said protein.
25. A method of producing a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9 comprising growing a recombinant cell containing the nucleic acid of claim 14 such that the encoded said protein is expressed by the cell, and recovering the expressed said protein.
26. A method of producing a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9 comprising growing a recombinant cell containing the nucleic acid of claim 20 such that the encoded said protein is expressed by the cell, and recovering the expressed said protein.

27. A pharmaceutical composition comprising a therapeutically effective amount of a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9; and a pharmaceutically acceptable carrier.
28. The pharmaceutical composition of claim 27 in which said protein is a human protein.
29. A pharmaceutical composition comprising a therapeutically effective amount of the protein of claim 5; and a pharmaceutically acceptable carrier.
30. A pharmaceutical composition comprising a therapeutically effective amount of the chimeric protein of claim 7; and a pharmaceutically acceptable carrier.
31. A pharmaceutical composition comprising a therapeutically effective amount of the nucleic acid of claim 11; and a pharmaceutically acceptable carrier.
32. A pharmaceutical composition comprising a therapeutically effective amount of the nucleic acid of claim 15; and a pharmaceutically acceptable carrier.
33. A pharmaceutical composition comprising a therapeutically effective amount of the nucleic acid of claim 16; and a pharmaceutically acceptable carrier.
34. A pharmaceutical composition comprising a therapeutically effective amount of the recombinant cell of claim 20; and a pharmaceutically acceptable carrier.
35. A pharmaceutical composition comprising a therapeutically effective amount of an antibody, or a fragment or derivative of an antibody containing the binding domain of the antibody, that immunospecifically binds to a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9; and a pharmaceutically acceptable carrier.

36. A method of treating or preventing a disease or disorder involving cardiac hypertrophy in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that promotes function of a protein or rRNA selected from the group consisting of CH-1, Desmin, Protein Kinase C-Binding Protein β 15, 5.8S rRNA, 18S rRNA and 28S rRNA.

37. The method according to claim 36 in which the disease or disorder is a pressure overload cardiac hypertrophy.

38. The method according to claim 36 in which the subject is a human.

39. The method according to claim 36 in which the molecule that promotes function of said protein is selected from the group consisting of said protein, a derivative or analog of said protein that is active in inhibiting cardiac hypertrophy, a nucleic acid encoding said protein, and a nucleic acid encoding a derivative or analog of said protein that is active in inhibiting cardiac hypertrophy.

40. A method of treating or preventing a disease or disorder involving cardiac hypertrophy in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule that inhibits function of a protein selected from the group consisting of CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, CH-9, α -Enolase, Antizyme Inhibitor, Biglycan, Cytochrome Oxidase I, Cytochrome Oxidase II, Cyclin G, D-binding protein, Fibrillin, Laminin α -1, p85 and Preproenkephalin .

41. The method according to claim 40 in which the molecule that inhibits function of said protein is selected from the group consisting of an antibody or a fragment or derivative thereof containing the binding region thereof against said protein, an antisense nucleic acid of a gene encoding said protein, and a nucleic acid comprising at least a portion of a gene encoding said protein into which a heterologous nucleotide sequence has been inserted such that said heterologous sequence inactivates the biological activity of at least a portion of the gene encoding said protein, in which the portion of the gene encoding said proteins flanks the heterologous sequence so as to promote homologous recombination with a genomic gene encoding said protein.

42. The method according to claim 40 in which the disease or disorder is pressure overload cardiac hypertrophy.

43. A method of diagnosing a disease or disorder characterized by detecting an aberrant level of CHAG RNA or protein in a subject, comprising measuring the level of said RNA or protein in a sample derived from the subject, in which an increase or decrease in the level of said RNA or protein, relative to the level of said RNA or protein found in an analogous sample not having the disease or disorder indicates the presence of the disease or disorder in the subject.

44. A method of diagnosing or screening for the presence of or a predisposition for developing a disease or disorder involving cardiac hypertrophy in a subject comprising measuring the level of a protein, RNA or functional activity selected from the group consisting of CH-1, Desmin, Protein Kinase C-Binding Protein β 15, 5.8S rRNA, 18S rRNA and 28S rRNA in a sample derived from the subject, in which a decrease in the level of said protein, RNA, or functional activity in the sample, relative to the level of said protein, RNA, or functional activity found in an analogous sample not having the disease or disorder or a predisposition for developing the disease or disorder, indicates the presence of the disease or disorder or a predisposition for developing the disease or disorder.

45. A method of diagnosing or screening for the presence of or a predisposition for developing a disease or disorder involving cardiac hypertrophy in a subject comprising measuring the level of a protein, RNA or functional activity selected from the group consisting of CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, CH-9, α -Enolase, Antizyme Inhibitor, Biglycan, Cytochrome Oxidase I, Cytochrome Oxidase II, Cyclin G, D-binding protein, Fibrillin, Laminin α -1, p85 and Preproenkephalin in a sample derived from the subject, in which an increase in the level of said protein, RNA, or functional activity in the sample, relative to the level of said protein, RNA, or functional activity found in an analogous sample not having the disease or disorder or a predisposition for developing the disease or disorder, indicates the presence of the disease or disorder or a predisposition for developing the disease or disorder.

46. A kit comprising in one or more containers a molecule selected from the group consisting of an antibody against a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9, a nucleic acid probe capable of hybridizing to a RNA selected from the group consisting of an RNA encoding CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9, or a pair of nucleic acid primers capable of priming amplification of at least a portion of a nucleic acid selected from the group consisting of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, and *CH-9*.

47. A kit comprising in a container a therapeutically effective amount of a protein selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9.


48. A method of identifying a molecule that specifically binds to a ligand selected from the group consisting of a protein, a fragment of the protein comprising a domain of the protein, and a nucleic acid encoding the protein or fragment, selected from the group consisting of CH-1, CH-2, CH-3, CH-4, CH-5, CH-6, CH-7, CH-8, and CH-9, comprising

- (a) contacting said ligand with a plurality of molecules under conditions conducive to binding between said ligand and said molecules; and
- (b) identifying a molecule within said plurality that specifically binds to said ligand.

49. A recombinant non-human animal in which an endogenous gene selected from the group consisting of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, and *CH-9* has been deleted or inactivated by homologous recombination or insertional mutagenesis of said animal or an ancestor thereof.

50. A recombinant non-human animal in which a gene selected from the group consisting of *CH-1*, *CH-2*, *CH-3*, *CH-4*, *CH-5*, *CH-6*, *CH-7*, *CH-8*, and *CH-9* is under control of a promoter that is not the native promoter of said gene.

Fig. 1



PANEL C

```
QUERY:      113   GATCTNGCTCCTATAGGCATCCGTTGGTAAACAATTGCTCCAGGTCTGTTGCCACCCCCA    54  
            ||||| ||||| ||||| ||||| | | ||||| ||||| ||||| |||||  
SBJCT:     568   GATCTGGCTCCCATAAGGTATCCGGGTGATGACCATTGCCCAAGGTCTGTTTGCCACCCCCA    627
```

,

```
QUERY:       53   CTGCTTACCACACTCTNCCANACAAAANTNCGCAACTTCTTGGCCANCACAGGTACC    1  
            ||||| ||||| ||||| ||||| | ||||| ||||| ||||| |||||  
SBJCT:     628   CTGCTGACCAGCCTCCCAGAGAAAGTGTGCAACTTCTTGGCCAGCCAAGTGCC        680
```


PANEL A

1 tccggagtgg acagccagta ggagtagtcg ttccctggagg cgaagtggca gacgttggtg
 61 atgttgca gaaggaaggg catggtgctg aacttgcgca gacagctgcc agccgtaccc
 121 aagtcctgac catgggccc ctcgtttcct tggacataga gcagagagta cccatggtaa
 181 agaattttgg tccctggggg acacagcggg tcatctcacn gtctgactat gcctgggtcac
 241 aaggaagcca tggtcacacag atgggggtacc

PANEL B

QUERY: 270 GGTACCCCATCTGTGGACCATGGCTTCCTTGTGACCAGGCATAGTCAGACNGTGAGATGA 211
 GGTACCCCATCTGTGGACCATGGCTTCCTTGTGACCAGGCATAGTCAGAC AGATGA
 SBJCT: 4443 GGTACCCCATCTGTGGACCATGGCTTCCTTGTGACCAGGCATAGTCAGACAAAC-AGATGA 4501

QUERY: 210 CCCGCTGTGTCCCCCAGGGACCAAAATTCCTTTACCATGGGTACTCTCTGCTCTATGTCCA 151
 CCC CTGTGTCCCCCAGGGACCAAAATTCCTTTACCATGG TACTCTCTGCTCTATGTCCA
 SBJCT: 4502 CCCACTGTGTCCCCCAGGGACCAAAATTCCTTTACCATGGATACTCTCTGCTCTATGTCCA 4561

QUERY: 150 AGGAAACGAGCGGGCCCATGGTCAGGACTTGGGTACGGCTGGCAGCTGTCTGCGCAAGTT 91
 AGG AACGAGCG GCCCCA GG CAGGACTTGGGTACGGCTGGCAGCTG CTGCG AAGTT
 SBJCT: 4562 AGGCAACGAGCGTGCCCAAGGCGCAGGACTTGGGTACGGCTGGCAGCTGCTGCGTAAGTT 4621

QUERY: 90 CAGCACCATGCCCTTCCTTCTGCAACATCAACAACGCTCTGCAACTTCGCCCTCCAGGAA 31
 CAGCACCATGCCCTT CTCTTCTGCAACATCAACAACGCTCTGCAACTTCGCCCTCCAGGAA
 SBJCT: 4622 CAGCACCATGCCCTTCTCTTCTGCAACATCAACAACGCTCTGCAACTTCGCCCTCCAGGAA 4681

QUERY: 30 CGACTACTCCTACTGGCTGTCCACTCCGGA 1
 CGACTACTC TACTGGCTGTCCAC CC GA
 SBJCT: 4682 CGACTACTCCTACTGGCTGTCCACGCCAGA 4711

Fig. 4

5/13

PANEL A

1	ggtaccttcn	atttggtccc	atgctatcnn	atccntaagg	atgccctggt	ttcccagcca
61	ncnnagtgtc	tcgaccncgn	aggattgect	gctgnctntn	cnntgacttt	tctgttcggg
121	a					

PANEL B

QUERY:	1	GGTACCTTCNATTTGTTCCCATGCTATCENNATCCNNTAAGGATGCCCTGGTTTCCCAGCCA	60
SBJCT:	687	GGTACCTTCAATGTGTTTCCCATGTTACCAACTCCATAAAGATGCCCTGGTTTCCCAGCCA	746
QUERY:	61	NCNNAGTGTCTGCACCCNGNAGGATTGCCCTGCTGNCNTNNCNNTGACTTTTCTGTCCGG	120
SBJCT:	747	ACCAGGTACTTGCACCCAGAGGATTGCCCTCCGACTACACAATCAGTTTCTATTCCGG	806
QUERY:	121	A	121
SBJCT:	807	A	807

Fig. 5

6/13

PANEL A

1 yggccacggc ggctgctggg gcntnancgg gttttctctca gggcaaatga tataaggctc
61 ggtacc

PANEL B

QUERY: 1 GGCCACGGCGGCTGCGGGCN-TNANCGGGTTTTCTCAGGCAATGATAT-AAGGCT 58
GGCCACGGCGG CT CG GGC T CGGGTTT TCAGG CAAATGAT AAGG T

SBJCT: 186 GGCCACGGCGGCTCCGAGGCTATCTACGGGTTTTTTTCAGGACAAATGATGCCAAGGGT 245

QUERY: 59 CGGTAC 64
GGTAC

SBJCT: 246 -GGTAC 250

Fig. 6

PANEL A

1	gtgcacacac actatagttt tcctgcttgt ccttnngttc tctctgggag atggacaacc
61	ctcaaaggca ctgattgntg acattnntag ctctgntcct tactcaggca gccagctcag
121	ccaaggcccg gtccaaggga tcc

PANEL B

QUERY: 143	GGATCCCTTGGACCGGGCCCTTGGCTGAGCTGGCTGCCCTGAGTAAGGANCAGAGCTANNAA 84
	GGATCC TTGGACCGGGCCCTTGGCTGAGCTGGCTGCCCTGAGTAAGGA CA AGC A AA
SBJCI: 2175	GGATCCCTTGGACCGGGCCCTTGGCTGAGCTGGCTGCCCTGAGTAAGGACCA-AGCCATCAA 2233
QUERY: 83	TGTCANCAATCAGTGCCTTTGAGGGTTGTCCATCTCCAGAGAGAACNNAAGGACAAGCA 24
	TGTCA CAATCAGTGCCTTTGAGGGTTGTCCATCTCCCA AGA A C A GG CAAGCA
SBJCI: 2234	TGTCACCAATCAGTGCCTTTGAGGGTTGTCCATCTCCCAAGACATCATATGG-CAAGCA 2292
QUERY: 23	GGAAAACTATAGTGTGTGCAC 1
	GGAAAACTAT TGTGTG GC C
SBJCI: 2293	GGAAAACTATGATGTGTGCGCGC 2315

Fig. 7

1 rgatcccaag tcacagcatt ttcccacgta actcgactct gaggccatag cctatccaca
61 gcctcctcgt cccctgcacc gccagtgtc tcactggctg tgttggagac gggaattgca
121 taagcctt

QUERY:	1	RGATCCCAAGTCACAGCATTTTCCCCACGTAACCTCGACTCTGAGGCCATAGCCTATCCACA	60
		+	
SBJCT:	1149	AGATCCCAAGTCACAGCATTTTCCCCACGTTACTCGACTCTGAGGCCATAGCCTATCCACA	1208
QUERY:	61	GCCTCCTCGTCCCTGACACCGCCAGTGTTCTCACTGGCTGTGTTGGAGACGGGAATTGCA	120
SBJCT:	1209	GCCTCCTCGTCCCTGACACCGCCAGTGTTCTCACTGGCTGTGTTGGAAACGGGAATTGCA	1268
QUERY:	121	TAAGCTT	127
SBJCT:	1269	TAAGCTT	1275

8/13

Fi. 8.

1 aagcttgac agatcaaaa aatggaacc gtgtggggac aggcaata aaaaaactca
61 cggtgcnatt ctcnncataa agcaaacgg tttaaatgca gcagtgtgan ttcttccan
121 ttccttctct gggatttcag gggatcc

QUERY:	147	GGATCCCCCTGAAATCCAGAGAGGAANTGGGAAGAANTCACACTGCTGCATTTAAACCG	88
		GGATCCCCCTGAAATCCC GAGAAG TGGGAAGAA TCA ACTG TGCATTTAA CG	
SBJCT:	3254	GGATCCCCCTGAAATCCCGGAGAAGAGCCTGGGAAGAA-TCAAACTGATGCATTTAAACGGC	3312
QUERY:	87	TTTCGCTTTATGNNGAGAAATNGCACCCGTGAGTTTTTTTATTGCTTGTCCCCACACGGT	28
		TT GCTTTA GAG AT GCACCGTGAG T TAT TG C TGTCCTCCACACGGT	
SBJCT:	3313	TTCTGCTTTACACAGAGGATCGCACCCGTGAGCCGTGCTATCTGTCTGTCTCCACACACGGT	3372
QUERY:	27	TCCATTTCTTTTGATCTGTGCAAGCTT 1	
		TC TTTCTTTTG TCTGTGCAAGCTT	
SBJCT:	3373	TCTGTTTCTTTTGGTCTGTGCAAGCTT 3399	

Fig. 9

10/13

PANEL A

1 gtgcacggac tgnaggctgt gctcgggcca gtggtgactg catttgccac aggactcatt
 61 tactgccacg ctctgctctt ganggtnttc cangtncnnn annantnnan nggtnanntn
 121 ntncaaatnt tncaactncn tnaaggtnaa nggginctggg ctncaaagaga acgtanctgg
 181 ttttggtttt gagatgggtgg aggcagtggg tgctgcttct cttgaactag gggcttcttc
 241 ttctgctgag cataggtgaa gctagc

PANEL B

QUERY: 265 CTAGCTTCACCTATGCTCAGCAGAGGAGAGAGCCCTAGTTCAAGAGAAGCAGCACCAC 206
 CTAGCTTCACCTATGCTCAGCAGAGGAGAGCCCTAGTTCAAGAGAAGCAGCACCAC
 SBJCT: 1173 CTAGCTTCACCTATGCTCAGCAGAGGAGAGCCCTAGTTCAAGAGAAGCAGCACCAC 1232

QUERY: 205 TGCCTCCACCATCTCAAAACCAAAACCAGNTACGTTCTCTTGNAG-CCCAGNCCCNTTNA 147
 GCCTCCACCA CTCAAAACCAAAACCAG TAGG TCTC TG AG CCCAG CCC TT A
 SBJCT: 1233 AGCCTCCACCATCTCAAAACCAAAACCAGTACGTTCTCTTGGAGGCCAGGCCCTTGA 1292

QUERY: 146 CCTTNANGNAGTTGNAANATTGTGNANNANTNACCNNTNANTNNTNNTNNGNACNTGGANN 87
 CC T A G AG T A A TTG A A T ACC A T T G AC TGGA
 SBJCT: 1293 CCCTGAAGGAGGTAGAGGAGTTGGAGCAGCTGACCCAGCAGCTGATGCAGGACATGGAAC 1352

QUERY: 86 ACCNTCAGAGGCAGAGCGTGGCAGTAAATGAGTCTCTGTGGCAAATGCAGTCA-CCACTGG 28
 ACC TCAGAGGCAGAGCGTGGCAGT AATGAGTCTCTGTGGCAAATGCA TCA CCACTGG
 SBJCT: 1353 ACCCTCAGAGGCAGAGCGTGGCAGTGAATGAGTCTCTGTGGCAAATGCAATCAGCCACTGG 1412

QUERY: 27 CCGGAGCACAGCCTNCAGTCCGTGCAC 1
 CCGG GCACAGCCT C GT CGTGCAC
 SBJCT: 1413 CCGGTGCACAGCCTGCGGTTCGTGCAC 1439

Fig. 10

TABLE I

Gene	Fragment	Enzyme Pair	% Difference	N-Fold Difference	Figure No.	SEQ. ID (DNA)
(CH1) Homologous to human <i>Short-chain alcohol dehydrogenase</i> and mouse <i>amyloid beta-peptide binding protein</i>	i0a0-114.7	BglII/Acc65I	-35.44	-1.5	See Figure 2	SEQ. ID NO:1
(CH2) Homologous to mouse α -1 Collagen Type III	b0p0-206.1	AgeI/BstYI	+282.85	+3.8	See Figure 3	SEQ. ID NO:2
(CH3) Homologous to mouse α -1 Collagen Type IV			+226.90	+3.3	See Figure 4	SEQ. ID NO:3
(CH4) Homologous to chicken Collagen Type XIV	l0a0-121	BspEI/Acc65I	+84.03	+1.8	See Figure 5	SEQ. ID NO:4
(CH5) Homologous to human 13kD DAP	a0e1-67	Acc65I/EaeI	+264.17	+3.6	See Figure 6	SEQ. ID NO:5
(CH6) Homologous to mouse and human <i>Gelsolin</i>	g0c0-142.1	BamHI/ApaI	+327.35	+4.3	See Figure 7	SEQ. ID NO:6
(CH7) Homologous to mouse <i>Osteonectin</i>	p0s0-127.4	BasYI/HindII	+158.80	+2.6	See Figure 8	SEQ. ID NO:7
(CH8) Homologous to mouse <i>Transglutaminase</i>	g0s0-145	BamHI/HindII	+98.33	+2.0	See Figure 9	SEQ. ID NO:8
(CH9) Homologous to mouse and human <i>Zyxin</i>	w0c0-266.2	NheI/KasI	+1983.33	+20.8	See Figure 10	SEQ. ID NO:9

12/13

TABLE II

Gene	Fragment	Enzyme Pair	% Difference	N-Fold Difference	GB Accession No.
<i>Rattus</i> sp. α -Enolase			+120.02	+2.2	Gber h35207
<i>Rat Antizyme Inhibitor</i>	m0 0 122.7	BopHI/HindIII	+101.29	+2.0	D50734
<i>Rattus norvegicus</i> Biglycan	i0m0-168.6	BgIII/BspHI	+243.64	+3.4	U17834
	i0i0-136	BgIII/SalI			
	i0p0-136.2	BspEI/BstYI			
	i0h0-95	BgIII/BstGI			
	i0h0-133	BgIII/BstGI			
	i031-189.7	BgIII/EaeI			
	p0e1-190	BstYI/EaeI			
<i>Rat Cytochrome Oxidase I</i>	m0s0-203.2	BspHI/HingIII	+231.90	+3.3	J01435
<i>Rattus norvegicus</i> Cytochrome Oxidase II	n0r0-387.3	BstGI/EcoRI	+202.30	+3.0	J01434
<i>Rattus norvegicus</i> Cyclin G	gli0-329	BgIII/XbaI	+235.23	+3.4	X70871
<i>Rat D-binding protein</i>			+85.87	+1.8	J03179
<i>Rattus norvegicus</i> Desmin	p0r0-259	BstYI/EcoRI	-45.39	-1.8	X73524
<i>Fibrillin</i>	i0m0-148.3	BgIII/BspHI			L19896
<i>Rattus norvegicus</i> Laminin α -1	p0r0-294	BstYI/EcoRI	+258.95	+3.6	X94551
<i>Rat Preproenkephalin</i>	m0n0-271.1	BapHI/BstGI	+235.57	+3.4	K02805
<i>Rattus norvegicus</i> Protein kinase C-binding protein α 15	g0s0-255.4	BamHI/HindIII	-81.00	-5.3	U48248
<i>Rattus norvegicus</i> p85	r0s0-44.7	EcoRI/HingIII	+332.90	+4.3	U42581
Human 28S rRNA gene			-80.30	-5.1	M11167

TABLE II (continued)

R. norvegicus genes for 5.8S, 18S, and 28S rRNAs					
Rat α -Skeletal Actin	bli0-199	BsrFI/BgIII	-69.21	-3.2	V01270
	IOeI-189.7	BgIII/EaeI	+265.50	+3.7	J00692
	p0eI-190	BstYI/EaeI			
	blp0-379.7	BsrFI/BstYI			
	m0n0-420.3	BspHI/BsrGI			
	m0v0-254	BsPHI/NgnoMI			
Rat ANF			+605.72	+7.1	K02062
Rat ANF precursor			+605.72	+7.1	X00665
Rat Atrial Natriuretic Peptide (ANP)	bli0-171.8	BsrFI/BgIII			X01118
	i0a0-136	BgIII/Acc65I	+471.76	+5.7	
Rat MLC2			+57.36	+1.6	M11851
α -Cardiac MHC	p0x0.49.5	BstYI			K01464
α -Cardiac MHC	bli0-427.4	BsrBI/BgIII			K01463
Rat Fibronectin	i0r0-131.9	BgII/EcoRI	+276.79	+3.8	X15906